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ABSTRACT
My doctoral studies focused on the fatty acid metabolism of the deadly
protozoan parasite, Trypanosoma brucei. Fatty acid metabolism in T. brucei can
be broadly divided into two pathways, synthesis and uptake. In Chapters 2-4 I
describe experiments investigating the parasite’s fatty acid synthesis pathway.
Chapter 2 contains the initial characterization of acetyl-CoA carboxylase (ACC) in
T. brucei. Knockdown of TbACC by RNA interference (RNAi) reduced parasite
virulence in a mouse model, suggesting that TbACC has the potential to be
utilized as a drug target. Chapters 3 and 4 explore the effects of two known ACC
inhibitors, the aryloxyphenoxypropionate herbicide, haloxyfop and the green tea
catechin, (−)-epigallocatechin-3-gallate (EGCG) on TbACC activity and parasite
growth. Both compounds inhibited TbACC enzymatic activity and parasite growth
in vitro. In Chapters 5 and 6 contain research that utilizes forward and reversegenetic techniques to study T. brucei fatty acid uptake. In Chapter 5 I begin to
characterize the role of the parasite’s acyl-CoA synthetase genes in fatty acid
uptake and growth. Further, I demonstrate that fatty acid uptake is in part a
protein mediated process. Chapter 6 describes an RNAi screen for genes
involved in T. brucei fatty acid uptake. Together these studies build upon our
knowledge of the unique fatty acid metabolism of T. brucei, bringing us one step
closer to a potential cure for this horrible disease.
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CHAPTER ONE
LITERATURE REVIEW
AFRICAN TRYPANOSOMIASIS
Trypanosoma brucei is an early-branching protozoan parasite transmitted
by the tsetse fly to its mammalian hosts. The parasite threatens over 6.2 million
square miles in sub-Saharan Africa (FAO, Food and Agricultural Organization of
the United Nations, 2007) where it causes fatal disease in humans. Between
1998 and 2004 annual cases of African sleeping sickness were estimated to
number 50,000 to 70,000 (WHO, 2010). More recently, in 2009, less than 10,000
cases were reported. In some regions the infection rate of human African
trypanosomiasis (HAT) is especially high, causing greater morbidity and mortality
than either HIV/AIDS or malaria (WHO, 2010).
Two subspecies of the parasite cause disease in humans. T. b.
gambiense is most common on the western side of the Nile rift valley and causes
a chronic infection that leads to death over a ~3 year period. T. b. rhodesiense is
found primarily on the eastern side of the Nile rift valley and causes an acute
infection that can result in death in as little as 3 weeks (Brun et al., 2010). T. b.
brucei is the subspecies we utilize for laboratory experiments. Humans are
resistant to infection by T. b. brucei because they possess a specialized type of
high density lipoprotein called trypanolytic factor (TLF) causes parasite lysis
when it is taken up via endocytosis (Wheeler, 2010). Cattle and other livestock
lack TLF and are therefore sensitive to infection by T. b. brucei and a related
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parasite, Trypanosoma congolense. These parasites are the causative agents of
a devastating livestock disease called nagana (Baumgaertner et al., 2008). The
disease makes agriculture in this lush, fertile landscape nearly impossible and
results in $4.5 billion dollars of trypanosome-related agricultural losses each
year. Much of the economic turmoil in this poverty-stricken region of sub-Saharan
Africa stems from the inability to establish an efficient agricultural system in this
uncultivatable “green desert” (FAO, Food and Agricultural Organization of the
United Nations, 2007).
HAT manifests two distinct clinical stages. In early-stage infections
parasites are restricted to the bloodstream and lymph. Typical early-stage
symptoms include fever, headache, and swollen lymph nodes. Late-stage
symptoms occur after the parasite has invaded the central nervous system.
Severe insomnia is often induced by disruptions of circadian rhythms. This
disruption causes the lethargic coma-like state that is characteristic of the
infection and the origin of the term “sleeping sickness”. Late-stage HAT may also
bring about psychological conditions ranging from apathy to irritability (Brun et
al., 2010).
African Trypanosomiasis Treatment
There is no vaccine for African trypanosomiasis because the antigenic
variability of the parasite confounds vaccine development (Brun et al., 2010;
Horn et al., 2010). Thus, current control options center on prevention and
chemotherapy. Prevention methods such as trapping, insecticide treatment, and
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behavioral changes (e.g. grazing at night) are costly and/or potentially toxic to
humans and cattle, while ultimately yielding incomplete protection (Enserink,
2007).
Successful treatment of HAT is dependent upon proper diagnosis of the
parasite subspecies and disease phase. Hemolymphatic infections are
diagnosed using either card agglutination tests or microscopic examination of
blood and lymph node aspirates. However, detection of late-stage HAT requires
a lumbar puncture to acquire cerebrospinal fluid (CSF) for analysis. Despite the
invasive nature of a lumbar puncture, CSF screening is considered a necessary
step in the diagnostic process, as two of the approved drugs are not suitable for
last-stage treatment because they do not efficiently cross the blood-brain barrier
(Fairlamb, 2003; WHO, 2010; Brun et al., 2010).
The five compounds currently available for treating sleeping sickness each
have substantial limitations (Fairlamb, 2003; Brun et al., 2010). Patients with an
early-stage infection are treated with either Suramin or Pentamidine. Suramin is
the front-line drug for early-stage T. b. rhodesiense infections. Besides having
immediate life-threating side-effects, the trypanocidal activity of Suramin is slow
and the mode of action remains a mystery. It is widely considered to have
multiple cellular targets, a notion supported by the fact that drug resistance in
field isolates has not been reported. Early-stage T. b. gambiense infections are
typically treated with Pentamidine. The drug has relatively high trypanocidal
activity, and resistance in field isolates has not been reported. The compound is
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taken up by at least three cell membrane transporters and causes a disruption in
kinetoplast DNA replication by inhibiting mitochondrial topoisomerase II.
Pentamidine is also believed to reduce polyamine biosynthesis by inhibiting
production of S-adenosylmethionine. However, Pentamidine has limited use
because it does not cross the blood-brain barrier and has limited efficacy against
T. b. rhodesiense.
Late-stage T. b. gambiense infections can be treated with Eflornithine. The
compound perturbs polyamine biosynthesis by irreversibly inhibiting ornithine
decarboxylase. Treatment with Eflornithine is reasonably effective, but the
medically-intensive administration (four daily infusions over 1-2 weeks) and high
cost often force care-givers to utilize Melarsoprol, a much less desirable
alternative. Because Melarsoprol is relatively inexpensive compared to
Eflornithine, it is the most common chemotherapeutic agent for treatment of latestage T. b. gambiense and T. b. rhodesiense infections. It is a highly-toxic,
organic derivative of arsenic. Melarsoprol kills 5% of patients receiving treatment
(McNeil, 2000). Drug administration is extremely painful because the waterinsoluble compound is dissolved in propylene glycol. Due to its widespread use,
reports of Melarsoprol resistance are common. Treatment failures as high as
30% have been reported in some regions (Fairlamb, 2003; WHO, 2010; Brun et
al., 2010).
Nifurtimox, a drug approved for treatment of Trypanosoma cruzi infection,
has also been utilized in combination with either Eflornithine or Melarsoprol to
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treat late-stage cases of sleeping sickness. The results of the clinical trials have
been somewhat conflicting, but a recent review of 9 different Nifurtimoxcombination therapy trials concluded that a Nifurtimox-Eflornithine combination
was better tolerated than a Nifurtimox-Melarsoprol combination or Melarsoprol
alone. Additionally, rates of relapse, a typical complication in treating late-stage
HAT, were low when Nifurtimox-Eflornithine combination therapy was utilized.
Thus, Nifurtimox combination therapies represent a new weapon in the battle
against sleeping sickness (Fairlamb, 2003; Lutje et al., 2010).
New drugs for the treatment of sleeping sickness are desperately needed.
Of the 5 currently used compounds, Eflornithine was developed most recently,
first synthesized in 1977. Suramin has been in use for over 90 years (Fairlamb,
2003). These facts highlight the desperate need for new drugs and drug targets,
making research into trypanosome biology of critical importance. My research
represents progress towards developing new treatments for sleeping sickness.
Trypanosoma brucei LIFE CYCLE
Within an infected mammalian host, the parasite lives and divides
extracellularly in the blood stream and in late-stage infections, the cerebrospinal
fluid. Rapid division occurs via binary fission, resulting in parasite titers
exceeding 1x109 parasites/mL. This spike in parasitemia is followed by a
developmental shift to the nonproliferative short stumpy form. As the infection
progresses, parasites begin to cross the blood-brain barrier and accumulate in
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the brain, eventually leading to coma and death (Matthews, 2005; Lee et al.,
2007).
The insect life stage begins when the tsetse fly takes a blood meal
containing short stumpy forms from an infected mammal. The parasites replicate
for a period in the insect’s midgut before traversing the midgut epithelium into the
hemolymph. They then navigate through the hemolymph to invade the salivary
glands where they undergo another developmental shift into metacyclic forms.
These metacyclic form parasites can then be transmitted to another mammalian
host when the fly takes its next blood meal (Matthews, 2005; Lee et al., 2007)
(Fig. 1.1).
Parasite Surface Coats
The surface coat proteins of the parasite are important for survival
throughout its life cycle. In the mammalian bloodstream form (BF), the surface
coat is composed of 107 identical copies of variant surface glycoprotein (VSG)
(Ferguson et al., 1984). Each VSG molecule is attached to the cell membrane by
a glycosylphosphatidylinositol (GPI) anchor whose fatty acid moiety is exclusively
the 14-carbon fatty acid, myristate (Ferguson et al., 1984). This dense VSG coat
allows the parasite to vary its surface antigens throughout the duration of an
infection. Over 1000 genes code for the proteinaceous portion of VSG, giving the
parasite a huge antigenic repertoire (Ferguson et al., 1999). This process of
antigenic variation allows the trypanosome to be a very successful parasite; the
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mammalian adaptive immune system is unable to mount an efficient attack
against the ever-changing parasite surface coat.
The insect midgut, procyclic form (PF) parasites also depend heavily on
their surface coat protein, procyclin (Richardson et al., 1988; Roditi et al., 1989).
Procyclin may play a major role in protecting the trypanosome against proteolytic
degradation while in the midgut of the tsetse fly (Acosta-Serrano et al., 2001).
Each of the 106 procyclins per cell is attached to the cell membrane by a lysoGPI anchor, each requiring two fatty acid molecules, either 16 or 18-carbons in
length (Butikofer et al., 1997). The parasite’s dependence upon GPI-anchored
surface coat proteins during two life cycle stages highlights the high demand for
copious quantities of fatty acids throughout its life cycle (Morita et al., 2000; Paul
et al., 2001).
Host Microenvironments
As the parasite moves through its life cycle, it encounters a number of
diverse microenvironments: the mammalian blood and brain/CSF; and the insect
midgut, hemolymph and salivary glands. Each of these environments is unique in
their nutrient content. One example of a dramatic shift in environmental fatty acid
availability occurs when the parasite moves across the blood-brain barrier; the
CSF contains 99.8% less lipids than the blood (Roheim et al., 1979). Fatty acids
are extremely important to the parasite. Besides constituting critical GPI anchor
components for essential cell surface proteins, fatty acids play both functional
roles (cell signaling molecules) and structural roles (principal elements of cellular
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membranes) within the cell. Because of the extremely variable conditions and
high demand for fatty acids, the parasite encounters host microenvironments
where the available fatty acids are insufficient. To compensate, T. brucei can
synthesize its own fatty acids. Thus, the parasites must have the ability to
efficiently regulate its mechanism for de novo synthesis of fatty acids to meet its
changing nutrient demands.
FATTY ACID SYNTHESIS
Fatty acid synthesis (FAS) occurs in cycles of four enzymatic reactions
that result in the extension of a growing acyl chain by two carbons with each
successive cycle. The first reaction in the cycle involves the condensation of an
acyl chain with a malonyl group, the two-carbon donor molecule; this reaction is
catalyzed by a ketoacyl synthase. The ketoacyl intermediate then undergoes a
reduction by ketoacyl reductase, dehydration by a dehydratase and final
reduction by enoyl reductase, yielding a fatty acyl chain two carbons greater in
length (Lee et al., 2007) (Fig. 1.2). While all FAS includes the same four basic
reactions, different types of FAS pathways have a number of important
distinctions.
FAS pathways are separated into two groups: the eukaryotic type I and
the prokaryotic-origin type II. The type I FAS pathway includes one or two very
large multifunctional proteins, while the type II pathway utilizes four separate
proteins, each with a discrete enzymatic function. Many eukaryotic organisms
possess both pathways. However, the type II pathway is typically restricted to
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organelles of prokaryotic origin (e.g., mitochondria, apicoplasts and chloroplasts)
(Goodman et al., 2007; Lee et al., 2007; Stephens et al., 2007). Some
eukaryotes also utilize microsomal elongases (ELO) as a component of their FAS
machinery. ELO pathways utilize the same cycle of enzymatic reactions as type I
or type II FAS, but typically extend only long chain fatty acids (16 to 18 carbons)
to very long chain fatty acids, greater than 20 carbons in length (Toke et al.,
1996; Oh et al., 1997; Moon et al., 2001). ELO pathways are also distinct
because they are associated with organellar membranes and utilize Coenzyme-A
(CoA) rather than acyl carrier protein as a carrier molecule for acyl intermediates.
T. brucei Fatty Acid Synthesis
Unlike most eukaryotes T. brucei lacks the typical components of the
cytosolic type I FAS. In lieu of the conventional FAS pathway, the parasite
depends completely upon an ELO pathway for the bulk synthesis of its fatty acids
(Lee et al., 2006). This ELO pathway is set apart from others by the ability to
synthesize fatty acids de novo from a 4-carbon primer, butyryl-CoA. The T.
brucei ELO pathway consists of four different ketoacyl-CoA synthases with
distinct, yet overlapping specificities for acyl-CoA chain lengths: ELO1 (C4:0 –
C10:0), ELO 2 (C10:0 – C14:0), ELO 3 (C14:0 – C18:0). There is a fourth
enzyme in the pathway, ELO4, but its use is restricted to elongation of long chain
unsaturated fatty acids. The two reductases in the pathway have also been
identified; the genome codes for two ketoacyl-CoA reductases and a single
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enoyl-CoA reductase. The pathway’s dehydratase has yet to be identified (Lee et
al., 2006; Lee et al., 2007).
The distinct yet overlapping activities of the ELO proteins allows for a very
efficient FAS mechanism in T. brucei. The modulation of each ELO’s enzymatic
activity allows for the preferential production of specific chain length fatty acids,
providing T. brucei the ability to adjust to its ever-changing environmental
conditions and demands for fatty acids (Lee et al., 2007). In addition, the need for
a dedicated FAS and elongation pathways is essentially eliminated, because the
ELO pathway serves both purposes.
T. brucei also possess a second FAS pathway, a mitochondrial type II
pathway. It consists of one acyl carrier protein (ACP), one ketoacyl-ACP
synthase, three ketoacyl-ACP reductases, one or more currently unidentified
dehydratases, and two enoyl-ACP reductases. Mitochondrial FAS is only
responsible for 10% of total the FAS in the parasite and its primary products are
C16:0 and C8:0. The C8:0 product is synthesized as a precursor for lipoic acid,
which is an important prosthetic group for multiple mitochondrial enzymes (Lee et
al., 2007; Stephens et al., 2007).
Both the mitochondrial and cytoplasmic FAS pathways of T. brucei are
essential for parasite growth. In both PF and BF parasites, reduction of ACP by
RNAi or conditional knockout resulted in reduced mitochondrial FAS and slowed
parasite growth in culture (Stephens et al., 2007). T. brucei exhibits a condition
and stage-specific requirement for cytoplasmic FAS. Reduction of enoyl-CoA

10

reductase by conditional knockout caused a growth phenotype only when PF
parasites were cultured in low-lipid media (Lee et al., 2006). This is not the case
in BF parasites; enoyl-CoA reductase was essential for growth in normal media
and in a mouse model (Soo Hee Lee, personal communication).
ACETYL-COA CARBOXYLASE
FAS requires a substantial amount of malonyl-CoA, as it donates two
carbons to the growing acyl-chain. Malonyl-CoA is generated by the
carboxylation of acetyl-CoA, a reaction catalyzed by acetyl-CoA carboxylase
(ACC). This is an ATP dependent reaction and therefore, is considered the first
committed step in FAS (Barber et al., 2005).
The T. brucei genome codes for a single ACC gene, which was
determined by homology to other ACCs (Aslett et al., 2010; TbGeneDB). TbACC
is a large multidomain enzyme, consisting of biotin carboxylase, biotin-carboxyl
carrier protein (BCCP), and carboxyl-transferase (CT) domains. The ACC
reaction proceeds forward in two steps. First, the carboxylation of the biotin
prosthetic group proceeds by adding a CO2 group from a bicarbonate molecule.
This is followed by the carboxyl transfer step, combining CO2 and acetyl-CoA,
resulting in the creation of the two-carbon donor malonyl-CoA (Lee et al., 2008).
Regulation of Acetyl-CoA Carboxylase
The enzymatic activity of ACC is controlled by multiple post-translational
modifications. Reversible phosphorylation is the best understood mechanism and
is conserved in all described ACCs (Barber et al., 2005). Increased
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phosphorylation causes a reduction in ACC activity. Both AMP-activated protein
kinase (AMPK) and protein kinase A phosphorylate ACC and have direct impact
on activity (Barber et al., 2005; Brownsey et al., 2006). Regulation of TbACC by
phosphorylation has yet to be demonstrated. However, experiments in our lab
have demonstrated that TbACC is indeed phosphorylated (Sunayan Ray,
personal communication).
Regulation of ACC activity by polymerization has also been reported. In
its basal state ACC exists as a dimer, but it is also capable of forming higher
order polymers (Kleinschmidt et al., 1969; Mackall et al., 1978; Thampy et al.,
1985; Barber et al., 2005). in vitro treatment of chicken liver extracts with
supraphysiological concentrations of citrate causes the enzyme to polymerize
into long filaments and increases enzymatic activity (Beaty et al., 1985). In
mouse liver the polymerization process is facilitated by the MIG12 protein. The
presence of MIG12 lowers the citrate concentration needed to induce ACC
polymerization and elevated activity (Kim et al., 2010). These filamentous
polymers dissociate in response to ACC’s product, malonyl-CoA (Beaty et al.,
1983). ACC polymers in the form of planar arrays have also been reported in
yeast and are believed to be active polymers (Schneiter et al., 1996).
Mammalian Acetyl-CoA Carboxylase
The mammalian genome contains two ACCs: ACC1 and ACC2. While
both catalyze the conversion of acetyl-CoA to malonyl-CoA, their products serve
very different functions in the cell. ACC1 is predominately involved in creating
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malonyl-CoA to be used in fatty acid synthesis, while the malonyl-CoA produced
by ACC2 is involved in regulating cellular energy usage. Malonyl-CoA is an
allosteric inhibitor of carnitine palmitoyltransferase 1 (CPT1), the enzyme
responsible for transporting long-chain fatty acids (LCFA) into the mitochondrion
(Harada et al., 2007). By inhibiting CPT1, high malonyl-CoA concentrations
reduce the rate of FA beta-oxidation within the mitochondrion. Low malonyl-CoA
levels activate CPT1 and increase the amount of LCFA available to the betaoxidation pathway. By this mechanism cells avoids futile cycling, preventing
simultaneous synthesis and oxidation of FA. This balance is believed to be
regulated by AMPK. Activation of AMPK causes increased phosphorylation and
inhibition of ACC (Bouzakri et al., 2008).
Acetyl-CoA Carboxylase Inhibitors
As a consequence of the huge cost associated with the development of
pharmaceuticals and the dire economic status of sub-Saharan Africa, critics
contend that even the identification of a perfect drug target would not result in a
commercially available therapy for African trypanosome infections. African
trypanosomiasis and similar infectious diseases are very low priorities for
pharmaceutical companies, so called “orphan diseases.” However, recent
research has implicated the human ACC pathway as playing a role in diabetes,
obesity, and some cancers, effectively sparking the interest of drug companies
(Lopaschuk et al., 2006; Tong et al., 2006; Choi et al., 2007; Folmes et al., 2007).
As a result, multiple drugs targeting human ACC are in the drug development
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pipeline, and many of their analogs have been synthesized in the process
(Cheng et al., 2006; Corbett et al., 2007). These compounds have the potential to
inhibit TbACC, thereby reducing the problem of African trypanosomiasis being an
“unprofitable” disease.
In addition to its potential use as a drug target for human disease, ACC
has long been recognized as a valuable target for chemical intervention in crop
management and fungicides. Current allosteric ACC inhibitors can be divided into
three distinct classes (Tong et al., 2006).
Class 1 inhibitors work by preventing transfer of the carboxyl group
from the BCCP domain to the acetyl-CoA substrate. The cyclohexanediones and
aryloxyphenoxypropionates, also known as DIMs and FOPs, are members of this
class. Haloxyfop targets the plastid ACCs of grasses by binding the CT domain
and causing conformational changes that render the enzyme inactive (Delye et
al., 2003; Zhang et al., 2004b; Xiang et al., 2009). Another class 1 inhibitor, 5(tetradecyloxy)-2-furancarboxylic acid (TOFA) accomplishes the same goal by a
different mechanism. Upon entering the cell, TOFA is converted to a CoA
thioester and competes for the acetyl-CoA binding pocket (Halvorson et al.,
1984; Tong et al., 2006).
Class 2 inhibitors are substituted bipiperidylcarboxamides. CP-640186
is the best characterized of the class 2 inhibitors. It interacts with ACC near the
BCCP domain and interferes with the biotin moiety (Zhang et al., 2004a).
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Class 3 inhibitors are polyketide fungicides. Soraphen A is the best
characterized class 3 compound. It binds ACC near the ATP binding pocket and
interferes with the carboxylation of the biotin moiety by preventing the
dimerization of the BC domain (Shen et al., 2004; Tong et al., 2006).
Many other naturally occurring products are also being explored as
inhibitory molecules. They are attractive because they are readily available and
many are currently approved for human consumption. The green tea catechin
(−)-epigallocatechin-3-gallate (EGCG) inhibits ACC activity in a non-allosteric
manner. EGCG activates AMPK and thereby increases ACC phosphorylation,
resulting in decreased ACC activity (Moon et al., 2007a; Moon et al., 2007b;
Huang et al., 2009).
In the third and fourth chapters of this dissertation I demonstrate the
effectiveness of haloxyfop and EGCG as TbACC inhibitors. Both molecules are
commercially available and have well-characterized modes of action, making
them useful tools in my efforts to characterize TbACC. These studies add to my
initial characterization of TbACC (Chapter 2) and build upon previously published
studies of haloxyfop and EGCG in related protozoan parasites. Taken together
the experiments described in Chapters 2-4 significantly extend our knowledge of
T. brucei FAS.
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EXTRACELLULAR LIPID UPTAKE
Mammalian lipid acquisition mechanisms can vary by tissue and cell type.
In this section I will present a generalized review of the best-characterized
mechanisms of lipid uptake.
A primary route of lipid acquisition is through endocytosis of lipoproteins.
Lipoproteins are made up of a polar surface layer, containing phospholipids,
apolipoproteins, and cholesterol and a nonpolar inner core that contains
triglycerides and cholesterol esters (Wasan et al., 2008). Lipoproteins are
internalized by endocytosis and transported to the lysosome, where the
components are liberated. In addition to bulk uptake of lipoproteins, specific
phospholipids can be acquired from donor lipoprotein particles and inserted
directly into the cell membrane (Engelmann et al., 2010).
A second major mechanism of lipid acquisition is through uptake of FAs.
FAs have very low aqueous solubility, and therefore are usually associated with
membranes or proteins, typically albumin in the mammalian bloodstream. To
become internalized, FAs must first dissociate from albumin and partition into the
outer leaflet of the phospholipid bilayer. This is followed by a flip-flop that
changes the orientation of the FA carboxyl head group from the outer to the inner
lipid-water interface. The FAs can then partition into the cell and become bound,
activated, or incorporated into more complex lipid species (Glatz et al., 2010).
This process follows biphasic kinetics. Partitioning into the lipid bilayer occurs
quickly, but internalization is much slower (Mellors et al., 1989). The flip-flop
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mechanism is widely considered the rate-limiting step in the uptake process
(Kampf et al., 2007a; Kampf et al., 2007b).
Uptake of FA is known to occur both by protein-mediated active transport
and passive diffusion (Glatz et al., 2010). Fatty acid transport protein 1 (FATP1)
is localized to the cellular membrane and actively moves fatty acids into the cell.
Other proteins, such as CD36 and the peripheral membrane fatty acid binding
protein, function by facilitating diffusion, binding FAs, and concentrating them on
membrane surface. Bound fatty acids are more easily partitioned into the
membrane than albumin-associated FAs, thus uptake rates are greatly
increased.
Lipid rafts, specifically caveolae, also appear to play a role in the FA
uptake process. Caviolin exhibits high-affinity FA binding. However, its major role
in FA uptake is to provide a plasma membrane docking site for CD36. CD36 is
predominantly localized to caveolae but is dispersed throughout the plasma
membrane when lipid rafts are disrupted by cholesterol depletion. This
mislocalization is accompanied by a reduction in FA uptake (Ehehalt et al., 2006;
Glatz et al., 2010).
Non-plasma membrane associated proteins also play a role in the uptake
of fatty acids. Before an internalized FA can be broken down for energy or
incorporated into a more complex lipid species, it must first be activated. The
activation process involves esterification to CoA by a family of enzymes called
acyl-CoA synthetases (ACS). Before a FA is activated or bound by a protein, it
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can leave the cell by outward passive diffusion. Esterification to CoA makes the
resulting acyl-CoA membrane-impermeant. Thus, ACS increases retention of
FAs that are internalized by facilitated or passive diffusion (Milger et al., 2006).
Lipid Uptake in Trypanosoma brucei
Multiple mechanisms for lipid uptake have been described in T. brucei. In
the mammalian bloodstream the parasite can take up both high and low density
lipoproteins via endocytosis (Coppens et al., 1995; Green et al., 2003). This
process is enhanced by a lipoprotein scavenger receptor (Green et al., 2003;
Thomson et al., 2009). PF T. brucei also likely utilizes a similar mechanism to
take up lipophorin (LP) from the tsetse hemolymph. Uptake of LP has been
demonstrated in the related parasite, Trypanosoma rangeli (Folly et al., 2003)
and the malaria parasite, Plasmodium gallinaceum (Atella et al., 2009). In
addition to endocytosis of lipoproteins, T. brucei has a specialized mechanism for
acquisition of phospholipids. This process involves the coordinated activity of
three proteins and has been validated in vitro for uptake of
lysophosphatidylcholine (Bowes et al., 1993).
To date little is known about the mechanisms of FA uptake in T. brucei.
Proteins involved in uptake of FAs in T. brucei have not yet been identified and
characterized. Early studies demonstrate that FA uptake follows similar biphasic
kinetics as described in humans (Voorheis,1980). This similarity in kinetics
suggests that, like in human FA uptake, both protein-mediated active transport
and passive diffusion are likely occurring. The T. brucei genome does contain 5
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ACSs, and some early characterization of the genes has been completed (Jiang
et al., 2000; Jiang et al., 2001; Jiang et al., 2004). However, characterization of
the enzymes in intact cells has not been previously undertaken. In Chapter 5 of
this dissertation, I present the first experiments examining the role of the TbACS
genes in T. brucei FA uptake and growth.
Additionally, because FA uptake likely plays a key role in the growth and
virulence of the parasite, I performed an RNAi library screen to identify novel
genes involved in this process. In Chapter 6 of this dissertation I describe the
screen and provide suggestions for improvements.
RNA INTERFERENCE IN Trypanosoma brucei
A number of genetic tools are available for use in T. brucei. The initial
description of RNAi in Caenorhabditis elegans (Fire et al., 1998) was followed
quickly by its discovery in T. brucei (Ngo et al., 1998). Soon after, a number of
genetic tools were developed to take advantage of the parasite’s RNAi
machinery to study the function of genes in forward and reverse genetic
experiments (Shi et al., 2000; Wang et al., 2000; LaCount et al., 2002; Morris et
al., 2002). The last decade has seen a steady increase in the use of RNAi as a
substitute for traditional knockouts or dominant negative mutants.
The popularity of RNAi over traditional gene knockouts can be attributed
to a number of factors. First, compared to creating deletion mutants through gene
knockouts, RNAi is quick and less labor intensive. Specifically, creating an RNAi
mutant involves a single cloning reaction and one stable transfection, whereas
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creating knockouts requires multiple rounds of cloning and transfection, due to
the diploid genome of T. brucei.
Second, RNAi provides researchers a tool to study essential genes
(Motyka et al., 2004; Balana-Fouce et al., 2007). With the exception of low-level
leaky expression, uninduced RNAi mutants have identical gene expression to
their parental cell lines. Induction of RNAi is achieved by addition of tetracycline
to the growth media, initiating synthesis of dsRNA and degradation of target
mRNA. The resulting phenotype can be effectively studied prior to the death of
the cell. Deletion of essential genes is not possible because it results in death of
the organism. An alternative approach, termed conditional knockout, involves
stably transfecting an ectopic gene copy prior to native gene deletion. Conditional
knockouts are even more labor intensive, and high ectopic gene expression
levels can become toxic to the cell.
While RNAi has proven to be a very powerful tool, it comes with its own
set of drawbacks. RNAi does not necessarily provide complete abolishment of
the target protein. Even when mRNA is degraded below the level of detection,
stable proteins can persist for the duration of an experiment. The level of protein
required for parasite growth or function of a metabolic pathway can vary widely
between genes and growth conditions (Krieger et al., 2000; Albert et al., 2005;
Caceres et al., 2010; Vigueira et al., 2011). Thus, RNAi may provide insufficient
knockdown to yield phenotypes for some genes. In these cases, alternative
strategies such as knockout, dominant negative, or transposon mutagenesis
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would need to be employed. A second limiting factor of RNAi is the rather rapid
reversion of mutants upon induction. Knockdown of essential genes, resulting in
death of the parasite, can promote selection for individuals that have mutated or
deleted the RNAi vector thereby rendering it nonfunctional (Motyka et al., 2004).
This phenomenon is most common in animal models, because drug selection for
maintenance of the dsRNA expression system is no longer imposed on the
parasite.
The T. brucei RNAi system has proven to be a very useful tool in my
research. I have utilized RNAi in reverse-genetics experiments to study the
function of TbACC and TbACS (see Chapters 2, 5). I have also used an RNAi
library (Morris et al., 2002) to perform a forward-genetics screen for genes
involved in fatty acid uptake (see Chapter 6).
In the future, I expect that the popularity of RNAi as a tool for research will
continue to grow. Recently, an exciting publication described the creation of an
efficient RNAi library in BF T. brucei (Alsford et al., 2011). This library was
utilized to identify genes essential for BF parasite growth in vitro, an important
first step in the development of new drug targets. In addition, great strides have
been made towards the creation of an inducible RNAi system in a related
trypanosome, Leishmania braziliensis (Lye et al., 2010). RNAi has been, and will
continue to be a valuable weapon in our fight against trypanosome infections.
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FIGURES
Figure 1.1: T. brucei life cycle. T. brucei is transmitted between mammalian
hosts by the blood-feeding tsetse fly. Figure adapted from Lee S.H., Stephens
J.L., and Englund P.T. (2007) A fatty-acid synthesis mechanism specialized for
parasitism. Nat Rev Microbiol 5: 287-297.
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Figure 1.2: Enzymatic reactions of fatty acid synthesis by the T. brucei
elongase pathway. Each cycle of four enzymatic reactions adds an additional 2
carbons in length to the acyl-CoA product. Figure adapted from Lee S.H.,
Stephens J.L., and Englund P.T. (2007) A fatty-acid synthesis mechanism
specialized for parasitism. Nat Rev Microbiol 5: 287-297.

23

REFERENCES
Acosta-Serrano, A., E. Vassella, M. Liniger, C. Kunz Renggli, R. Brun, I. Roditi
and Englund, P. T. (2001) The surface coat of procyclic Trypanosoma
brucei: programmed expression and proteolytic cleavage of procyclin in
the tsetse fly. Proc Natl Acad Sci U S A 98: 1513-1518.
Albert M.A., Haanstra J.R., Hannaert V., Van Roy J., Opperdoes F.R., Bakker
B.M., and Michels P.A. (2005) Experimental and in silico analyses of
glycolytic flux control in bloodstream form Trypanosoma brucei. J Biol
Chem 280: 28306-28315.
Alsford S., Turner D.J., Obado S.O., Scnchez-Flores A., Glover L., Berriman M.,
Hertz-Fowler C., and Horn D. (2011) High-throughput phenotyping using
parallel sequencing of RNA interference targets in the African
trypanosome. Genome Res 21: 915-924.
Aslett M., Aurrecoechea C., Berriman M., Brestelli J., Brunk B.P., Carrington M.,
et al. (2010) TriTrypDB: A functional genomic resource for the
Trypanosomatidae. Nucleic Acids Res 38: D457-62.
Atella G.C., Bittencourt-Cunha P.R., Nunes R.D., Shahabuddin M., and SilvaNeto M.A. (2009) The major insect lipoprotein is a lipid source to mosquito
stages of malaria parasite. Acta Trop 109: 159-162.
Balana-Fouce R., and Reguera R.M. (2007) RNA interference in Trypanosoma
brucei: A high-throughput engine for functional genomics in
trypanosomatids? Trends Parasitol 23: 348-351.
Barber M.C., Price N.T., and Travers M.T. (2005) Structure and regulation of
acetyl-CoA carboxylase genes of metazoa. Biochim Biophys Acta 1733: 128.
Baumgaertner J., Gilioli G., Tikubet G., and Gutierrez A.P. (2008) Eco-social
analysis of an east African agro-pastoral system: Management of tsetse
and bovine trypanosomiasis. Ecol Econ 65: 125-135.
Beaty N.B., and Lane M.D. (1985) Kinetics of citrate-induced activation and
polymerization of chick liver acetyl-CoA carboxylase. Ann N Y Acad Sci
447: 23-37.
Beaty N.B., and Lane M.D. (1983) The polymerization of acetyl-CoA carboxylase.
J Biol Chem 258: 13051-13055.

24

Bouzakri K., Austin R., Rune A., Lassman M.E., Garcia-Roves P.M., Berger J.P.,
et al. (2008) Malonyl CoenzymeA decarboxylase regulates lipid and
glucose metabolism in human skeletal muscle. Diabetes 57: 1508-1516.
Bowes A.E., Samad A.H., Jiang P., Weaver B., and Mellors A. (1993) The
acquisition of lysophosphatidylcholine by African trypanosomes.
J.Biol.Chem. 268: 13885-13892.
Brownsey R.W., Boone A.N., Elliott J.E., Kulpa J.E., and Lee W.M. (2006)
Regulation of acetyl-CoA carboxylase. Biochem Soc Trans 34: 223-7.
Brun R., Blum J., Chappuis F., and Burri C. (2010) Human African
trypanosomiasis. Lancet 375: 148-159.
Butikofer P., Ruepp S., Boschung M., and Roditi I. (1997) 'GPEET' procyclin is
the major surface protein of procyclic culture forms of Trypanosoma brucei
brucei strain 427. Biochem. J. 326: 415-423.
Caceres A.J., Michels P.A., and Hannaert V. (2010) Genetic validation of
aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets
in Trypanosoma brucei. Mol Biochem Parasitol 169: 50-54.
Cheng J.F., Huang Y., Penuliar R., Nishimoto M., Liu L., Arrhenius T., et al.
(2006) Discovery of potent and orally available malonyl-CoA
decarboxylase inhibitors as cardioprotective agents. J Med Chem 49:
4055-4058.
Choi C.S., Savage D.B., Abu-Elheiga L., Liu Z.X., Kim S., Kulkarni A., et al.
(2007) Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout
mice increases total energy expenditure, reduces fat mass, and improves
insulin sensitivity. Proc Natl Acad Sci U S A 104: 16480-16485.
Coppens I., Levade T., and Courtoy P.J. (1995) Host plasma low density
lipoprotein particles as an essential source of lipids for the bloodstream
forms of Trypanosoma brucei. J.Biol.Chem. 270: 5736-5741.
Corbett J.W., and H. H.J.,Jr. (2007) Inhibitors of mammalian acetyl-CoA
carboxylase. Recent Patents Cardiovasc Drug Discov 2: 162-80.
Delye C., Zhang X.Q., Chalopin C., Michel S., and Powles S.B. (2003) An
isoleucine residue within the carboxyl-transferase domain of multidomain
acetyl-coenzyme A carboxylase is a major determinant of sensitivity to
aryloxyphenoxypropionate but not to cyclohexanedione inhibitors. Plant
Physiol 132: 1716-1723.

25

Ehehalt R., Fullekrug J., Pohl J., Ring A., Herrmann T., and Stremmel W. (2006)
Translocation of long chain fatty acids across the plasma membrane--lipid
rafts and fatty acid transport proteins. Mol Cell Biochem 284: 135-140.
Engelmann B., and Wiedmann M.K. (2010) Cellular phospholipid uptake: Flexible
paths to coregulate the functions of intracellular lipids. Biochim Biophys
Acta 1801: 609-616.
Enserink M. (2007) Entomology. welcome to Ethiopia's fly factory. Science 317:
310-313.
Fairlamb A.H. (2003) Chemotherapy of human African trypanosomiasis: Current
and future prospects. Trends Parasitol 19: 488-494.
FAO, Food and Agricultural Organization of the United Nations. (2007) Ethiopian
fly factory guns for "poverty insect".
Ferguson M.A., and Cross G.A. (1984) Myristylation of the membrane form of a
Trypanosoma brucei variant surface glycoprotein. J Biol Chem 259: 30115.
Ferguson M.A., Brimacombe J.S., Brown J.R., Crossman A., Dix A., Field R.A.,
et al. (1999) The GPI biosynthetic pathway as a therapeutic target for
African sleeping sickness. Biochim Biophys Acta 1455: 327-40.
Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. (1998)
Potent and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature 391: 806-811.
Folly E., Cunha e Silva N.L., Lopes A.H., Silva-Neto M.A., and Atella G.C. (2003)
Trypanosoma rangeli uptakes the main lipoprotein from the hemolymph of
its invertebrate host. Biochem Biophys Res Commun 310: 555-561.
Folmes C.D., and Lopaschuk G.D. (2007) Role of malonyl-CoA in heart disease
and the hypothalamic control of obesity. Cardiovasc Res 73: 278-287.
Glatz J.F., Luiken J.J., and Bonen A. (2010) Membrane fatty acid transporters as
regulators of lipid metabolism: Implications for metabolic disease. Physiol
Rev 90: 367-417.
Goodman C.D., and McFadden G.I. (2007) Fatty acid biosynthesis as a drug
target in apicomplexan parasites. Curr Drug Targets 8: 15-30.

26

Green H.P., Del Pilar Molina Portela M., St Jean E.N., Lugli E.B., and Raper J.
(2003) Evidence for a Trypanosoma brucei lipoprotein scavenger receptor.
J Biol Chem 278: 422-427.
Halverson D.L., and McCune S.A. (1984) Inhibition of fatty acid synthesis in
isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 11: 851-856.
Harada N., Oda Z., Hara Y., Fujinami K., Okawa M., Ohbuchi K., et al. (2007)
Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient
mice. Mol Cell Biol 27: 1881-8.
Horn D., and McCulloch R. (2010) Molecular mechanisms underlying the control
of antigenic variation in African trypanosomes. Curr Opin Microbiol 13:
700-705.
Huang C.H., Tsai S.J., Wang Y.J., Pan M.H., Kao J.Y., and Way T.D. (2009)
EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression
through activation of AMPK in p53 positive and negative human hepatoma
cells. Mol Nutr Food Res 53: 1156-1165.
Jiang D.W., and Englund P.T. (2001) Four Trypanosoma brucei fatty acyl-CoA
synthetases: Fatty acid specificity of the recombinant proteins. Biochem J
358: 757-761.
Jiang D.W., Ingersoll R., Myler P.J., and Englund P.T. (2000) Trypanosoma
brucei: Four tandemly linked genes for fatty acyl-CoA synthetases. Exp
Parasitol 96: 16-22.
Jiang D.W., Werbovetz K.A., Varadhachary A., Cole R.N., and Englund P.T.
(2004) Purification and identification of a fatty acyl-CoA synthetase from
Trypanosoma brucei. Mol Biochem Parasitol 135: 149-152.
Kampf J.P., and Kleinfeld A.M. (2007a) Is membrane transport of FFA mediated
by lipid, protein, or both? an unknown protein mediates free fatty acid
transport across the adipocyte plasma membrane. Physiology (Bethesda)
22: 7-14.
Kampf J.P., Parmley D., and Kleinfeld A.M. (2007b) Free fatty acid transport
across adipocytes is mediated by an unknown membrane protein pump.
Am J Physiol Endocrinol Metab 293: E1207-14.
Kim C.W., Moon Y.A., Park S.W., Cheng D., Kwon H.J., and Horton J.D. (2010)
Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12
provides a tertiary level of regulation of fatty acid synthesis. Proc Natl
Acad Sci U S A 107: 9626-9631.

27

Kleinschmidt A.K., Moss J., and Lane D.M. (1969) Acetyl coenzyme A
carboxylase: Filamentous nature of the animal enzymes. Science 166:
1276-1278.
Krieger S., Schwarz W., Ariyanayagam M.R., Fairlamb A.H., Krauth-Siegel R.L.,
and Clayton C. (2000) Trypanosomes lacking trypanothione reductase are
avirulent and show increased sensitivity to oxidative stress. Mol Microbiol
35: 542-552.
LaCount D.J., Barrett B., and Donelson J.E. (2002) Trypanosoma brucei FLA1 is
required for flagellum attachment and cytokinesis. J Biol Chem 277:
17580-17588.
Lee C.K., Cheong H.K., Ryu K.S., Lee J.I., Lee W., Jeon Y.H., and Cheong C.
(2008) Biotinoyl domain of human acetyl-CoA carboxylase: Structural
insights into the carboxyl transfer mechanism. Proteins 72: 613-24.
Lee S.H., Stephens J.L., and Englund P.T. (2007) A fatty-acid synthesis
mechanism specialized for parasitism. Nat Rev Microbiol 5: 287-297.
Lee S.H., Stephens J.L., Paul K.S., and Englund P.T. (2006) Fatty acid synthesis
by elongases in trypanosomes. Cell 126: 691-699.
Lopaschuk G.D., and Stanley W.C. (2006) Malonyl-CoA decarboxylase inhibition
as a novel approach to treat ischemic heart disease. Cardiovasc Drugs
Ther 20: 433-439.
Lutje V., Seixas J., and Kennedy A. (2010) Chemotherapy for second-stage
human African trypanosomiasis. Cochrane Database Syst Rev 8:
CD006201.
Lye L.F., Owens K., Shi H., Murta S.M., Vieira A.C., Turco S.J., Tschudi C., Ullu
E., and Beverley S.M. (2010) Retention and loss of RNA interference
pathways in trypanosomatid protozoans. PLoS Pathog 10: e1001161.
Mackall J.C., Lane M.D., Leonard K.R., Pendergast M., and Kleinschmidt A.K.
(1978) Subunit size and paracrystal structure of avian liver acetyl-CoA
carboxylase. J Mol Biol 123: 595-606.
Matthews K.R. (2005) The developmental cell biology of Trypanosoma brucei. J
Cell Sci 118: 283-90.
McNeil D.G.J. (2000) Drug makers and 3rd world: Study in neglect. New York
Times .

28

Mellors A., and Samad A. (1989) The aquisition of lipids by African
trypanosomes. Parasitology Today 5: 239-244.
Milger K., Herrmann T., Becker C., Gotthardt D., Zickwolf J., Ehehalt R., et al.
(2006) Cellular uptake of fatty acids driven by the ER-localized acyl-CoA
synthetase FATP4. J Cell Sci 119: 4678-4688.
Moon H.S., Lee H.G., Choi Y.J., Kim T.G., and Cho C.S. (2007a) Proposed
mechanisms of (-)-epigallocatechin-3-gallate for anti-obesity. Chem Biol
Interact 167: 85-98.
Moon H.S., Chung C.S., Lee H.G., Kim T.G., Choi Y.J., and Cho C.S. (2007b)
Inhibitory effect of (-)-epigallocatechin-3-gallate on lipid accumulation of
3T3-L1 cells. Obesity (Silver Spring) 15: 2571-2582.
Moon Y.A., Shah N.A., Mohapatra S., Warrington J.A., and Horton J.D. (2001)
Identification of a mammalian long chain fatty acyl elongase regulated by
sterol regulatory element-binding proteins. J Biol Chem 276: 4535845366.
Morita Y.S., Paul K.S., and Englund P.T. (2000) Specialized fatty acid synthesis
in African trypanosomes: Myristate for GPI anchors. Science 288: 140143.
Morris J.C., Wang Z., Drew M.E., and Englund P.T. (2002) Glycolysis modulates
trypanosome glycoprotein expression as revealed by an RNAi library.
Embo J 21: 4429-38.
Motyka S.A., and Englund P.T. (2004) RNA interference for analysis of gene
function in trypanosomatids. Curr Opin Microbiol 7: 362-8.
Ngo H., Tschudi C., Gull K., and Ullu E. (1998) Double-stranded RNA induces
mRNA degradation in Trypanosoma brucei. Proc Natl Acad Sci U S A 95:
14687-92.
Oh C.S., Toke D.A., Mandala S., and Martin C.E. (1997) ELO2 and ELO3,
homologues of the saccharomyces cerevisiae ELO1 gene, function in fatty
acid elongation and are required for sphingolipid formation. J Biol Chem
272: 17376-17384.
Paul K.S., Jiang D., Morita Y.S., and Englund P.T. (2001) Fatty acid synthesis in
African trypanosomes: A solution to the myristate mystery. Trends
Parasitol 17: 381-7.

29

Richardson J.P., Beecroft R.P., Tolson D.L., Liu M.K., and Pearson T.W. (1988)
Procyclin: An unusual immunodominant glycoprotein surface antigen from
the procyclic stage of African trypanosomes. Mol.Biochem.Parasitol. 31:
203-216.
Roditi I., Schwarz H., Pearson T.W., Beecroft R.P., Liu M.K., Richardson J.P., et
al. (1989) Procyclin gene expression and loss of the variant surface
glycoprotein during differentiation of Trypanosoma brucei. J.Cell.Biol. 108:
737-746.
Roheim P.S., Carey M., Forte T., and Vega G.L. (1979) Apolipoproteins in
human cerebrospinal fluid. Proc Natl Acad Sci U S A 76: 4646-9.
Schneiter R., Hitomi M., Ivessa A.S., Fasch E.V., Kohlwein S.D., and Tartakoff
A.M. (1996) A yeast acetyl coenzyme A carboxylase mutant links verylong-chain fatty acid synthesis to the structure and function of the nuclear
membrane-pore complex. Mol Cell Biol 16: 7161-72.
Shen, Y., S. L. Volrath, S. C. Weatherly, T. D. Elich and Tong, L. (2004) A
mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A
carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol
Cell 16: 881-891.
Shi H., Djikeng A., Mark T., Wirtz E., Tschudi C., and Ullu E. (2000) Genetic
interference in Trypanosoma brucei by heritable and inducible doublestranded RNA. RNA 6: 1069-1076.
Stephens J.L., Lee S.H., Paul K.S., and Englund P.T. (2007) Mitochondrial fatty
acid synthesis in Trypanosoma brucei. J Biol Chem 282: 4427-4436.
TbGeneDB. Trypanosoma brucei GeneDB.
Thampy K.G., and Wakil S.J. (1985) Activation of acetyl-CoA carboxylase.
purification and properties of a Mn2+-dependent phosphatase. J Biol
Chem 260: 6318-23.
Thomson R., Samanovic M., and Raper J. (2009) Activity of trypanosome lytic
factor: A novel component of innate immunity. Future Microbiol 4: 789796.
Toke D.A., and Martin C.E. (1996) Isolation and characterization of a gene
affecting fatty acid elongation in Saccharomyces cerevisiae. J Biol Chem
271: 18413-18422.

30

Tong L., and J. H.H.,Jr. (2006) Acetyl-coenzyme A carboxylases: Versatile
targets for drug discovery. J Cell Biochem 99: 1476-88.
Vigueira P.A., and Paul K.S. (2011) Requirement for acetyl-CoA carboxylase in
Trypanosoma brucei is dependent upon the growth environment. Mol
Microbiol 80: 117-132.
Voorheis H.P. (1980) Fatty acid uptake by bloodstream forms of Trypanosoma
brucei and other species of the kinetoplastida. Mol Biochem Parasitol 1:
177-186.
Wang Z., Morris J.C., Drew M.E., and Englund P.T. (2000) Inhibition of
Trypanosoma brucei gene expression by RNA interference using an
integratable vector with opposing T7 promoters. J Biol Chem 275: 401749.
Wasan K.M., Brocks D.R., Lee S.D., Sachs-Barrable K., and Thornton S.J.
(2008) Impact of lipoproteins on the biological activity and disposition of
hydrophobic drugs: Implications for drug discovery. Nat Rev Drug Discov
7: 84-99.
Wheeler R.J. (2010) The trypanolytic factor-mechanism, impacts and
applications. Trends Parasitol 26: 457-464.
WHO W.H.O. (2010) WHO fact sheet on African trypanosomiasis.
Xiang S., Callaghan M.M., Watson K.G., and Tong L. (2009) A different
mechanism for the inhibition of the carboxyltransferase domain of acetylcoenzyme A carboxylase by tepraloxydim. Proc Natl Acad Sci U S A 106:
20723-20727.
Zhang H., Tweel B., Li J., and Tong L. (2004a) Crystal structure of the
carboxyltransferase domain of acetyl-coenzyme A carboxylase in complex
with CP-640186. Structure 12: 1683-1691.
Zhang H., Tweel B., and Tong L. (2004b) Molecular basis for the inhibition of the
carboxyltransferase domain of acetyl-coenzyme-A carboxylase by
haloxyfop and diclofop. Proc Natl Acad Sci U S A 101: 5910-5915.

31

CHAPTER TWO
REQUIREMENT FOR ACETYL-COA CARBOXYLASE IN Trypanosoma brucei
IS DEPENDENT UPON THE GROWTH ENVIRONMENT
Patrick A. Vigueira and Kimberly S. Paul
Department of Biological Sciences, Clemson University, Clemson, SC
ABSTRACT
Trypanosoma brucei, the causative agent of human African
trypanosomiasis, possesses two fatty acid synthesis pathways: a major de novo
synthesis pathway in the ER and a mitochondrial pathway. The 2-carbon donor
for both pathways is malonyl-CoA, which is synthesized from acetyl-CoA by
Acetyl-CoA Carboxylase (ACC). Here, we show that T. brucei ACC shares the
same enzyme architecture and moderate ~30% identity with yeast and human
ACCs. ACC is cytoplasmic and appears to be distributed throughout the cell in
numerous puncta distinct from glycosomes and other organelles. ACC is active in
both bloodstream and procyclic forms. Reduction of ACC activity by RNA
interference (RNAi) resulted in a stage-specific phenotype. In procyclic forms,
ACC RNAi resulted in 50-75% reduction in fatty acid elongation and a 64%
reduction in growth in low lipid media. In bloodstream forms, ACC RNAi resulted
in a minor 15% decrease in fatty acid elongation and no growth defect in culture,
even in low lipid media. However, ACC RNAi did attenuate virulence in a mouse
model of infection. Thus, the requirement for ACC in T. brucei is dependent upon
the growth environment in two different life cycle stages.
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INTRODUCTION
The deadly protozoan parasite Trypanosoma brucei, the causative agent
of African sleeping sickness in humans and Nagana in livestock, is vectored by
the bloodsucking tsetse fly and infects the blood and cerebrospinal fluid of its
human and animal hosts. As it transits through its life cycle, the parasite
encounters a number of different host microenvironments that differ in their
availability of key nutrients such as proteins and lipids, including fatty acids. For
example, there is a ~300X lower concentration of lipids in the cerebrospinal fluid
compared to blood (Lentner, 1981). One important function of fatty acids in T.
brucei is to anchor cell surface glycoproteins as part of their
glycosylphosphatidylinositol (GPI) anchors. These cell surface glycoproteins play
key roles in the parasite’s ability to evade host defenses. For example, switching
of the GPI-anchored Variant Surface Glycoprotein (VSG) surface coat via
antigenic variation protects T. brucei against immune attack in the mammalian
bloodstream (reviewed in Morrison et al., 2009; Mansfield and Paulnock, 2005).
Similarly, the GPI-anchored procyclin proteins may protect T. brucei against
proteolytic attack in the tsetse midgut (Acosta-Serrano et al., 2001). The parasite
has two ways to supply itself with fatty acids: acquire fatty acids from the host or
synthesize its own fatty acids de novo (Smith and Bütikofer, 2010). There is a
significant difference between the energy required for fatty acid uptake and
synthesis: uptake of a 16-carbon fatty acid by passive diffusion would require 1
ATP for activation to its CoA derivative, while synthesis of the same 16-carbon
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fatty acyl CoA would require 6 ATPs and 12 reducing units (Lee et al., 2006).
Thus, fatty acid uptake is likely preferred over the more energy intensive fatty
acid synthesis pathway. However, when the host fatty acid supply is insufficient,
the parasite must then synthesize its own fatty acids to meet its needs.
T. brucei has two fatty acid synthesis pathways: the fatty acid elongase
pathway of the endoplasmic reticulum that serves as the major pathway for
synthesis (Lee et al., 2006), and a minor pathway in the mitochondrion that
catalyzes the synthesis of mitochondrial fatty acids (Stephens et al., 2007; Guler
et al., 2008). T. brucei fatty acid elongation consists of a conserved cycle of
reactions that starts with the condensation of the 2-carbon donor, malonyl-CoA,
with an acyl-CoA primer (4–18 carbons long) followed by reduction, dehydration,
and reduction steps to yield a fatty acyl chain that is two carbons longer. MalonylCoA is synthesized from acetyl-CoA by Acetyl-CoA Carboxylase (ACC), a
member of the biotin-dependent carboxylase family of enzymes (Jitrapakdee and
Wallace, 2003). The ACC reaction is catalyzed in two steps: first, the ATPdependent carboxylation of the biotin prosthetic group, followed by transfer of the
carboxyl group from biotin to the acceptor acetyl-CoA. Because the synthesis of
malonyl-CoA requires the hydrolysis of ATP, the ACC reaction is considered the
first committed step in fatty acid synthesis and is a well-documented control point
for the regulation of this pathway in mammals and yeast (reviewed in Tehlivets et
al., 2007; Saggerson, 2008).
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As T. brucei can acquire fatty acids from the host as well as synthesize
them, the parasite likely has a mechanism to modulate its fatty acid synthesis
pathway(s) in response to the environmental supply. Two published observations
support this idea. First, bloodstream form T. brucei labeled with [3H]myristate
(C14:0) in whole blood showed no elongation, but cells labeled in medium with
only 5% serum lipids showed efficient elongatation of [3H]myristate into longer
fatty acids (Doering et al., 1993). Second, T. brucei midgut procyclic forms grown
in lipid-depleted medium had up-regulated the entire fatty acid elongase pathway
compared to cells grown in normal medium (Lee et al., 2006). We propose that
this ability to control fatty acid synthesis in response to the environment is critical
to the process of host adaptation, allowing maximal usage of host resources to
conserve energy that otherwise would be used for biosynthesis. To begin
elucidating the mechanism(s) by which T. brucei fatty acid synthesis is regulated
in response to the environment, we focused on ACC because it catalyzes the first
committed step of fatty acid synthesis, is known to be highly regulated by multiple
mechanisms in other systems, and could theoretically control flux through the
fatty acid synthesis pathway via the availability of its key substrate, malonyl-CoA.
Here, we performed an initial characterization of T. brucei ACC. We show
that ACC has a punctate cytoplasmic localization and that ACC is required by
procyclic forms for growth in culture under lipid-limited conditions and by
bloodstream forms for full virulence in mice.
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RESULTS
Comparison of T. brucei ACC to other ACCs
Alignment analysis revealed that the overall domain structure of T. brucei ACC is
similar to eukaryotic-type multi-domain ACCs, with an N-terminal biotin
carboxylase domain, a C-terminal carboxyltransferase domain, and a biotin
carboxyl carrier domain sandwiched in the middle (Barber et al., 2005) (Fig. 2.1).
Despite this conservation in overall enzyme architecture, T. brucei ACC shares
limited overall identities of 31% and 33% with S. cerevisiae ACC and human
ACC1, respectively, while human and yeast ACCs shared a slightly higher 44%
identity (Fig. 2.2). Comparison of T. brucei ACC with ACCs from Trypanosoma
cruzi and Leishmania major revealed a much higher degree of conservation
among the trypanosomes, with 58% (Tb vs. Lm), 60% (Tc vs. Lm), and 66% (Tb
vs. Tc) identities. As expected, overall sequence similarity was highest in the
regions constituting the core of the biotin carboxylase domain,
carboxyltransferase domain, and the residues surrounding the biotin attachment
site (Fig. 2.2 and Fig. 2.3). Most of the residues shown by X-ray crystallography
and/or mutational analysis to be involved in substrate binding and catalysis are
conserved (see residues marked by asterisks in Fig. 2.2 and 2.3) (Thoden et al.,
2000; Zhang et al., 2003; Shen et al., 2004; Tong, 2005; Lee et al., 2008; Chou
et al., 2009). In contrast, the large linker region between the biotin carboxyl
carrier and the carboxyltransferase domains showed less conservation (Fig. 2.2
and 2.3), presumably reflecting its primarily structural role.
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In addition, the predicted T. brucei ACC gene has a very short 7 amino
acid N-terminal sequence prior to the first conserved residue of the biotin
carboxylase domain, compared to that of S. cerevisiae ACC (36 amino acids)
and the human ACC1 isoforms (17 - 132 amino acids) (Fig. 2.2; National Center
for Biotechnology Information protein database). This short N-terminal sequence
might be conserved in trypanosomatids, as the L. major ACC N-terminus
appears to be equally truncated (Fig. 2.3). In most human ACC1 and ACC2
variants, the N-terminal leader sequence contains a conserved serine (e.g.
Ser117 in ACC1 isoform 1), which is a key site of post-transcriptional regulation
by AMP-activated protein kinase (AMPK) (Barber et al., 2005). In contrast, the
S. cerevisiae ACC N-terminus lacks this phosphorylation site and is instead
regulated by SNF1/AMPK phosphorylation at other serine residues within the
poorly conserved linker between the BCCP and CT domains (Fig. 2.1) (Woods et
al., 1994; Shirra et al., 2001; Ficarro et al., 2002; Tehlivets et al., 2007). Like S.
cerevisiae ACC, the T. brucei ACC N-terminal leader also lacks the conserved
serine, and thus may be regulated at other sites or by distinct mechanisms from
those controlling human ACC.
ACC is expressed in both bloodstream and procyclic forms
The TriTrypDB indicates that the T. brucei genome encodes a single
predicted ACC isoform (Tb927.8.7100) (Aslett et al., 2009), which was confirmed
by Southern blotting (data not shown). Northern analysis of total mRNA revealed
that the ACC mRNA is ~8.8 Kb and is transcribed in both bloodstream and
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procyclic form life cycle stages (Fig. 2.4A). ACC (and other biotinylated proteins)
can be detected on western blots using streptavidin conjugated to horseradish
peroxidase (SA-HRP), which recognizes the biotin prosthetic group (Nikolau et
al., 1985, Haneji and Koide, 1989). In addition to ACC, the T. brucei genome
contains one other biotinylated protein: the 74 kD alpha subunit of
3-methylcrotonyl-CoA carboxylase (Tb927.8.6970), which is a mitochondrial
enzyme involved in amino acid degradation. SA-HRP blotting of bloodstream and
procyclic form lysates revealed a predominant >200 kD band, roughly consistent
with the predicted size of ACC (243 kD) (Fig. 2.4B and 2.5B) given the resolving
power of the gel in this size range. The 74 kD alpha subunit of the
3-methylcronotonyl-CoA carboxylase was not readily detected in total lysates, but
could be detected in partially purified mitochondrial fractions (data not shown).
Although additional cross-reacting bands become evident upon longer
exposures, we show that the >200 kD band is specifically depleted upon ACC
RNAi, as discussed below (Fig. 2.9B). Finally, ACC enzyme activity was detected
in both bloodstream and procyclic form lysates and was dependent upon the
addition of ATP and acetyl-CoA (Fig. 2.4C). Taken together, these data show
that ACC is expressed and active in both life cycle stages.
ACC is cytoplasmic and localized to numerous puncta
Multiple prediction algorithms (WoLF PSORT, TargetP/SignalP, and
PredoTar) found no known targeting motifs in the ACC protein, predicting ACC to
be cytosolic (Horton et al., 2007; Emanuelsson et al., 2007; Small et al., 2004).
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To experimentally assess the localization of ACC, we used an epitope-tagging
strategy to create a procyclic form cell line (PF ACC-myc) with a c-myc tag fused
to the C-terminus of ACC. To minimize the possibility of mislocalizing the tagged
protein due to over-expression of an ectopic copy, we tagged the genomic locus
of only one ACC allele. Using immunoprecipitation with anti-c-myc antibody
covalently linked to beads, we found that ACC-myc immunoprecipitates
possessed ACC activity, while control immunoprecipitates from untagged cells
were inactive (Fig. 2.5). This result indicates that the myc-tagged ACC allele
encoded a functional enzyme.
First, we subjected lysates of PF ACC-myc cells to sub-cellular
fractionation by differential centrifugation (see Fig. 2.6A for scheme) and
analyzed the fractions by SDS-PAGE and western blotting (Fig. 2.6B). ACC-myc
showed a fractionation pattern similar to the cytoplasmic marker HSP70, and
distinct from the markers for the glycosome and ER. Moreover, the ACC-myc
fractionation pattern was the same as that of native ACC in both PF ACC-myc
cells (Fig. 2.6B) and wild-type procyclic cells (data not shown), indicating that the
c-myc epitope was not affecting the localization of the tagged ACC.
Next, we examined the sub-cellular localization of ACC by
immunofluorescence microscopy. ACC-myc was not uniformly distributed in the
cytoplasm, but instead localized to a multitude of small distinct puncta (Fig. 2.7
and 2.8, panels B, D, J, N, R, and V). Wild-type cells had no visible fluorescent
signal at the same exposure time (Fig. 2.8, panels F and H) and only a faint haze
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with an exposure 3.5 times longer (data not shown). A field of cells captured at a
lower magnification demonstrated that specific labeling with the anti-c-myc
antibody was reflected in the whole cell population (Fig. 2.8, panels C, D, G, and
H). The ACC puncta did not co-localize with markers for the cytoplasm
(cytoplasmic HSP70), the glycosomes (pyruvate phosphate dikinase, aldolase,
and glyceraldehyde phosphate dehydrogenase), the ER (BiP), or the
mitochondrion (lipoamide dehydrogenase) (Fig. 2.8, panels M-P, I-L, Q-T, and UX, respectively). Furthermore, the distribution of ACC-myc is distinct from that of
Nile Red-stained lipid droplets (Fig. 2.8, panels Y and Z), Golgi (Ho et al., 2006;
Ramirez et al., 2008), and acidocalcisomes, which are larger and less numerous
(de Jesus et al., 2010; Fang et al., 2007).
RNA interference of ACC is efficient in both bloodstream and procyclic
forms
Because our attempts to delete both alleles of ACC were unsuccessful,
we chose to assess the functional role of ACC in T. brucei using the pZJM RNAi
vector to induce knockdown of ACC mRNA in bloodstream and procyclic cells
(Wang et al., 2000; Morris et al., 2001). Northern analysis of total RNA showed
that induction of RNAi reduced ACC mRNA by 76% in bloodstream forms and
85% in procyclic forms (Fig. 2.9A). Similar results were obtained with at least four
independent clones (data not shown). Like others, we have observed that the
ACC RNAi cells can undergo RNAi reversion (Chen et al., 2003; Motyka and
Englund, 2004). By day 25, northern analysis showed that procyclic cells had
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completely recovered expression of ACC mRNA, even though ACC dsRNA was
still being produced (data not shown). SA-HRP blotting revealed the loss of ACC
protein over 10 days of RNAi (Fig. 2.9B). A separate analysis of 4 independent
inductions showed that four days of ACC RNAi reduced ACC protein by 91 ± 7%
in both bloodstream and procyclic forms. Four days of ACC RNAi also
significantly reduced ACC activity in lysates (Fig. 2.9C), with an 87 ± 1% and 90
± 1% reduction in bloodstream and procyclic cells, respectively (Fig. 2.10A and
B). Finally, ACC RNAi resulted in no growth inhibition in either bloodstream and
procyclic cells (Fig. 2.9D), with doubling times of 8 h and 15 h, respectively
(Fig. 2.10C). Fluorescence microscopy revealed that ACC RNAi resulted in no
gross defects in cell morphology, or in the structure of the mitochondrion, ER, or
nuclear/mitochondrial DNA as revealed by immunostaining with specific
antibodies to a mitochondrial marker (lipoamide dehydrogenase), an ER marker
(BiP), or by staining with the DNA intercalating dye DAPI (data not shown).
Effect of ACC RNAi on overall lipid metabolism
To look for ACC RNAi-induced changes in fatty acid metabolism, ACC
RNAi cells were incubated with [3H]laurate (C12:0) or [3H]myristate (C14:0),
which can be elongated by the fatty acid elongase pathway and incorporated into
lipids. Analysis of the labeled lipids by thin-layer chromatography (TLC) in the
absence of RNAi showed labeling of neutral lipids at the top, free fatty acids comigrating with the free fatty acid marker, myristate (Myr), and various
phospholipids co-migrating above and below the phospholipid marker,
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phosphatidylcholine (PtdC) (Fig. 2.11A, lanes 1, 3, 5, and 7). Migrating below the
phospholipids, we also observed labeling of the bloodstream form specific lipids,
Glycolipids A and C (and their intermediates) (Buxbaum et al., 1994), which are
precursors to the VSG GPI-anchor (Fig. 2.11A, lanes 5 and 7). In procyclic forms,
ACC RNAi resulted in little change in the overall labeling patterns of [3H]laurate
or [3H]myristate, except for an accumulation of free fatty acids and one of the
phospholipids (indicated by asterisk; likely phosphatidylethanolamine based on
its migration) (Fig. 2.11A, lanes 2 and 4). In bloodstream forms, ACC RNAi
labeling resulted in no change in the species labeled by [3H]laurate (Fig. 2.11A,
lanes 5 and 6). In contrast, ACC RNAi reduced incorporation of [3H]myristate into
phospholipids (Fig. 2.11A, lanes 7 and 8), while no loss of labeling was observed
in the bloodstream-specific Glycolipids A and C.
ACC is required for elongation of fatty acids
We next examined the effect of ACC RNAi on the major pathway for fatty
acid synthesis in T. brucei. Because the cell-free fatty acid elongation assay
bypasses the ACC step (Morita et al., 2000b), we examined fatty acid elongation
in vivo. Cells labeled with [3H]laurate (C12:0) and [3H]myristate (C14:0), which
should be converted to longer fatty acids if the elongase pathway is functioning
(Lee et al., 2006), were analyzed for elongation products using reverse-phase
TLC. In uninduced procyclic forms, both [3H]laurate and [3H]myristate were
elongated to products up to 18 carbons (Fig. 2.11B, lanes 1 and 3). ACC RNAi in
procyclics resulted in a 74 ± 6% and 53 ± 5% inhibition of [3H]laurate and
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[3H]myristate elongation, respectively (Fig. 2.11B, lanes 2 and 4). Uninduced
bloodstream forms readily elongated [3H]laurate (Fig. 2.11B, lane 5), but little
[3H]myristate elongation occurred (Fig. 2.11B, lane 7). ACC RNAi in bloodstream
forms resulted in a 15 ± 5% inhibition of [3H]laurate elongation (Fig. 2.11B, lane
6), and completely abolished the minor elongation that occurred with
[3H]myristate (Fig. 2.11B, lane 8).
Effect of ACC RNAi on growth in low-lipid media
Even though ACC RNAi reduced elongase activity, the cells were still able
to grow normally in culture (Fig. 2.9D). Because T. brucei can also readily
acquire fatty acids from the medium (Dixon et al., 1971; Voorheis, 1980; Bowes
et al., 1993; Lee et al., 1999; Coppens et al., 1995), we assessed the growth of
ACC RNAi cells in low lipid media. ACC RNAi in bloodstream forms still showed
no effect on growth in two different formulations of low lipid medium compared to
the uninduced control (Fig. 2.12A). In contrast, ACC RNAi in procyclic forms
reduced growth by 64% in low lipid medium (Fig. 2.12B). Furthermore, 68% of
this growth defect could be reversed by the addition of 35 µM stearate (C18:0),
suggesting that the growth defect arose from a lack of fatty acids rather than
some other limiting factor in the medium. Finally, pre-adaptation of bloodstream
and procyclic cells by growth in low lipid media for 10 days prior to induction of
ACC RNAi did not enhance the effect of ACC RNAi on growth (Fig. 2.13).
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ACC is required for full virulence in mice
To assess the virulence of ACC RNAi cells, NIH Swiss mice (n=10 per
group) were either left untreated (uninduced control) or treated with doxycycline
(a bioavailable tetracycline analog) in their drinking water to induce ACC RNAi.
Mice were then infected intra-peritoneally with 1 x 105 freshly thawed
bloodstream form ACC RNAi trypanosomes. The uninduced control infection
resulted in a mean time-to-death of 12.7 days by Kaplan-Meier survival analysis
(Fig. 2.14). However, when ACC RNAi was induced in the doxycycline-treated
mice, the mean time-to-death was significantly increased to 22.3 days (p =
0.0021, Wilcoxon test).
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DISCUSSION
Among the protozoa, only the ACCs of the Apicomplexan parasites
Toxoplasma gondii and Plasmodium falciparum have been characterized. These
Apicomplexans possess two eukaryotic-type multi-domain ACC isozymes: a
plastid ACC1 that functions in plastid de novo fatty acid synthesis and a cytosolic
ACC2, with proposed functions in fatty acid elongation, polyketide synthesis, and
mitochondrial fatty acid synthesis (Zuther et al., 1999; Jelenska et al., 2001;
Gardner et al., 2002; Waller et al., 2003; Mazumdar and Striepen, 2007). Here,
we have performed the first characterization of the sole trypanosome ACC
isozyme in bloodstream and procyclic forms and explored its role in fatty acid
metabolism.
The cytosolic punctate distribution of ACC-myc in T. brucei has not been
observed previously in other eukaryotes and thus, appears to be novel. What are
these puncta? They could represent a fixation artifact from the paraformaldehye.
However, ACC-myc showed the same punctate pattern when cells were fixed in
cold methanol, suggesting this is not the case (data not shown). The puncta
could also represent non-specific aggregation due to the c-myc epitope tag. Four
reasons argue against this: first, ACC-myc showed the same fractionation pattern
as native ACC, suggesting that the myc tag has no significant effect upon the
sub-cellular distribution of ACC; second, ACC-myc immunoprecipitates possess
ACC activity, suggesting that the myc tag did not affect enzyme function; third,
because the myc tag was incorporated into the genomic locus, ACC-myc is likely
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expressed at endogenous levels rather than at the high levels associated with
epitope-tag artifacts; fourth, one previous report of a cytosolic myc-tagged protein
showed diffuse staining in T. brucei rather than the puncta we observe for ACC
(Peterson et al., 1997).
An intriguing alternative is that these puncta might represent polymerization
of ACC in T. brucei. Mammalian and avian ACCs polymerize into filaments
(Kleinschmidt et al., 1969; Mackall et al., 1978), and there is evidence suggesting
yeast ACC may also polymerize (Schneiter et al., 1996). In birds and mammals,
ACC polymerization is dynamic and the polymer form is the active form (Ashcraft
et al., 1980; Beaty and Lane, 1983; Beaty and Lane, 1985; Thampy and Wakil,
1988; Kim et al., 2010). Whether they are non-specific aggregates or polymers,
the nature of the ACC puncta must be independently confirmed using an
alternative epitope tag or an antibody to native T. brucei ACC before their
function can begin to be explored.
Among unicellular eukaryotes, ACC has been most extensively
characterized in the yeasts. In both S. cerevisiae and Schizosaccharomyces
pombe, deletion of ACC is lethal (Hasslacher et al., 1993; Saitoh et al., 1996),
while a reduction in ACC activity leads to growth inhibition and a range of defects
in nuclear and vacuolar membrane function (Saitoh et al., 1996; Schneiter et al.,
1996; Schneiter et al., 2000). Thus, we predicted that ACC RNAi would reduce
overall lipid biosynthesis activity, resulting in growth inhibition in T. brucei.
Instead, we found that bloodstream form and procyclic cells differed in the effect
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of ACC RNAi upon fatty acid elongation and growth in culture. We also found that
the effect of ACC RNAi was dependent upon the growth environment.
Based on our results, we propose that procyclic form T. brucei is
dependent upon ACC only when environmental lipids are limiting. It is well known
that T. brucei can readily take up and use lipids from their environment (Dixon et
al., 1971; Voorheis, 1980; Bowes et al., 1993; Lee et al., 1999; Coppens et al.,
1995). Thus, in normal medium, procyclic cells primarily rely on fatty acid uptake
to satisfy their needs, rather than de novo synthesis. Therefore, reduction of fatty
acid elongation upon ACC RNAi had a limited effect on overall lipid metabolism
because the cells were already relying upon exogenous lipids. In low lipid
medium, however, the procyclics require ACC and fatty acid elongation to
compensate for the fatty acid deficit. Under these conditions, reduction of ACC
activity and fatty acid elongation rendered the cells unable to grow efficiently.
This growth defect of procyclic ACC RNAi cells in low lipid conditions is very
similar to that seen with RNAi of the enoyl-CoA reductase in the fatty acid
elongation pathway (Lee et al., 2006), consistent with the coupling of these
enzymes into the same metabolic pathway.
In bloodstream forms, the response to ACC RNAi differed significantly
from procyclic forms. Despite efficient knockdown of ACC activity, fatty acid
elongation was only moderately reduced, and the cells exhibited no growth
defect in either normal or low lipid media. This suggests that in cultured
bloodstream forms, the fatty acid elongation pathway may not be very dependent
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upon ACC. This result was unexpected for two reasons: first, in all other
eukaryotes examined to date, fatty acid synthesis and elongation are dependent
upon malonyl-CoA supplied by ACC; second, bloodstream form cells have a high
demand for myristate to anchor their VSG surface coat, which is a relatively
scarce fatty acid in serum and scarcer still in standard culture medium (Paul et
al., 2001). One possible explanation is that the residual ~10% ACC activity
supports sufficient fatty acid elongation. If true, this suggests that the level of
ACC expression in bloodstream forms is at >10-fold excess over what is required
for growth in culture. Other metabolic enzymes, such as trypanothione reductase
(Krieger et al., 2000) and several glycolytic enzymes (Albert et al., 2005; Caceres
et al., 2010), have been reported to be present in excess, though a 75-90%
knockdown of these enzymes did cause an observable growth defect.
In contrast to procyclics, loss of ACC had little apparent impact upon
bloodstream forms in culture, except one notable effect upon the metabolism of
[3H]myristate. As previously reported (Doering et al., 1993; Morita et al., 2000b),
very little elongation of [3H]myristate occurs in bloodstream forms, likely resulting
from the exclusive use of myristate as the fatty acid moiety in the VSG GPIanchors (Ferguson et al., 1988). However, under ACC RNAi conditions, we
observed a general loss in the incorporation of [3H]myristate into phospholipids,
while incorporation into the VSG GPI anchor precursors, Glycolipids A and C was
preserved. Thus, ACC RNAi revealed a partitioning of the myristate pool, where
the myristoylation of the GPI anchors takes priority over incorporation into
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phospholipids. This phenomenon has been observed previously (Doering et al.,
1993; Morita et al., 2000b), and highlights the special importance of myristate in
bloodstream form T. brucei. Morita et al. reported that myristate produced by the
ELO pathway was preferentially incorporated into the VSG GPI anchors. Here,
we show that exogenous myristate is likewise preferentially incorporated into the
VSG GPI anchors, perhaps by special delivery from acyl-CoA binding protein
(Milne and Ferguson, 2000), or by one or more acyl-CoA synthetases, four of
which can efficiently activate myristate to myristoyl-CoA (Jiang and Englund,
2001).
Low levels of ACC were sufficient for growth of bloodstream forms in
culture, even in low lipid media where the fatty acid elongase pathway is known
to be up-regulated (Lee et al., 2006). Yet ACC RNAi led to decreased virulence
in a mouse model of infection. One major difference between in vitro culture and
growth in the animal host is the presence of the host’s immune system. Thus,
one likely explanation for the reduced virulence is that ACC RNAi reduced the
ability of the parasite to evade the immune system. The primary means of T.
brucei to avoid the host’s adaptive immune system is antigenic variation, in which
a “new” VSG variant is trafficked to the surface while the “old” VSG variant is
either shed from the cell surface or internalized and degraded (Seyfang et al.,
1990; Mansfield and Paulnock, 2005). Furthermore, VSG itself is constantly
recycling off and back on to the cell surface via coupled endocytosis/exocytosis
(Engstler et al., 2004). Perhaps the ACC RNAi cells are compromised in their
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ability to maintain their VSG coat due to problems in trafficking and/or recycling.
This phenomenon has been observed previously for conditional knockouts of
phosphatidylinositol synthase and neutral sphingomyelinase (Young and Smith,
2010; Martin and Smith, 2006).
Another important immune evasion strategy of T. brucei is the
endocytosis-mediated clearance of antibodies bound to the surface of the
parasite (Schwede and Carrington, 2010). Under immune pressure, T. brucei
dramatically increases its endocytic activity in order to clear complementactivating surface immune complexes (Balber et al., 1979; Russo et al., 1993;
O'Beirne et al., 1998; Engstler et al., 2007; Natesan et al., 2007). Thus, the ACC
RNAi cells may be unable to meet the increased demand in lipid synthesis
arising from the dramatic upregulation in membrane turnover in the animal host.
The resulting failure to adequately clear surface antibody complexes would then
lead to reduced virulence.
Although the survival of the mice was increased under ACC RNAi
induction, the mice were unable to clear the infection and ultimately, nearly all
succumbed. The mice’s inability to clear the infection is likely due to the
emergence of RNAi revertants through positive selection and the fact that
antibiotic selection of the transgenes necessary for RNAi (T7 polymerase and Tet
repressor) was not maintained during infection to avoid drug toxicity (Lecordier et
al., 2005; Jetton et al., 2009). Supporting this idea, trypanosomes isolated from
an induced mouse late in infection (~107 parasites/ml) were shown to be

51

expressing ACC protein by SA-HRP blotting, though the level of ACC detected
was less than that in trypanosomes isolated from a control uninduced mouse
(data not shown).
This work extends our understanding of fatty acid synthesis in T. brucei
and points to the importance of exogenous sources of fatty acids in the overall
lipid metabolism of these parasites. Finally our data raise key questions about
how T. brucei senses environmental fatty acids and transduces this information
into regulatory decisions governing its fatty acid metabolism. Such processes are
key to survival, enabling the parasite to adapt its fatty acid metabolism to each
host environment to satisfy its lipid needs while minimizing wasteful energy
expenditure.
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MATERIALS AND METHODS
Reagents
All chemicals and reagents were purchased from Thermo Fisher Scientific
and Sigma except: Minimum Essential Medium Eagle (MEM), Iscove’s Modified
Dulbecco’s Medium (IMDM), 4’-6-diamidino-2-phenylindole (DAPI) (Invitrogen),
Serum Plus (JRH Biosciences), delipidated fetal bovine serum (FBS) (Cocalico
Biologicals), poly-L-lysine solution and normal goat serum (Electron Microscopy
Sciences). [α-32P]dATP (Perkin-Elmer), and [14C]NaHCO3, and [3H]-labeled fatty
acids (American Radiolabeled Chemicals). The mouse monoclonal 9E10 anti-cmyc antibody was from Santa Cruz Biotechnology. The rabbit polyclonal
antibodies to BiP and cytoplasmic HSP70 were generously provided by Dr. Jay
Bangs (University of Wisconsin-Madison) (Bangs et al., 1993; McDowell et al.,
1998). The rabbit polyclonal anti-lipoamide dehydrogenase antibody was a kind
gift of Dr. Luise Krauth-Siegel (University of Heidelberg) (Schoneck et al., 1997).
The rabbit polyclonal 2841D anti-glycosome antibody was a generous gift from
Dr. Marilyn Parsons (Seattle Biomedical Research Institute) (Parker et al., 1995)
and recognizes three glycosomal enzymes: Pyruvate Phosphate Dikinase
(PPDK) (~100 kD), Aldolase (~41 kD), and Glyceraldehyde Phosphate
Dehydrogenase (GAPDH) (~39 kD).
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Trypanosome Strains and Cell Lines
Wild-type procyclic and bloodstream form T. brucei strain 427 were
provided by Dr. Paul Englund (Johns Hopkins School of Medicine). Procyclic and
bloodstream form T. brucei transgenic cell lines containing genomicallyintegrated Tet repressor and T7 polymerase (29-13 and 90-13 respectively (Wirtz
et al., 1999; Hirumi and Hirumi, 1989)) were generously provided by Dr. George
Cross (Rockefeller University). Bloodstream form parasites were grown in HMI-9
medium (Hirumi and Hirumi, 1989) containing 10% heat-inactivated FBS/10%
Serum Plus and supplemented with 2.5 µg/ml G418, 5 µg/ml hygromycin, and
2.5 µg/ml phleomycin, as needed. Procyclic form parasites were grown in SDM79 medium (Brun and Shonenberger, 1979) containing 10% heat-inactivated
FBS and supplemented with 15 µg/ml G418, 50 µg/ml hygromycin, and 2.5 µg/ml
phleomycin, as needed.
Preparation of Low-Lipid Media
The only source of lipids in media comes from the serum additives.
According to the manufacturers, both Serum Plus and delipidated FBS contain
~20% serum lipids. Two types of low-lipid HMI-9 media were prepared.
Delipidated medium (DL) was prepared with 10% Serum Plus and 10%
delipidated FBS. Serum Plus only medium (SP) was prepared with 10% Serum
Plus only. Thus, the DL and SP media contain serum lipids equivalent to 4% and
2% FBS, respectively, compared to 12% for normal HMI-9 medium. For procyclic
cells, low-lipid DL medium was prepared with 10% delipidated FBS, and
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contained serum lipids equivalent to 2% FBS, compared to 10% for normal SDM79. For fatty acid rescue experiments, a final concentration of 35 µM stearate
(C18:0) was added to the medium.
RNA Purification and Northern Analysis
Total RNA was purified and northern analysis was performed as
previously described (Wang et al., 2000), except 1 x 107 cell equivalents or 10-15
µg of total RNA was loaded per lane and blots probed with a 32P-labeled DNA
probe corresponding to the same ACC sequence used for ACC RNAi (see
below).
Preparation of Cell Lysates
Hypotonic lysates were prepared as described (Morita et al., 2000b). We
also prepared lysates using an alternative method developed for
radioimmunoprecipitation assays (RIPA): 1 x 108 cells were washed twice in
BBSG (50 mM Bicine-Na+ pH 8, 50 mM NaCl, 5 mM KCl, 70 mM glucose) and
the final cell pellet frozen on dry ice. The frozen pellet was overlaid with 100 µl
TBS-RIPA buffer (1X Tris-Buffered Saline (TBS), 2 mM EDTA, 0.5 mM DTT, 1%
(v/v) nonidet P-40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS)
supplemented with 0.5 µg/ml leupeptin, 1 mM phenylmethanesulfonyl fluoride
(PMSF), 0.1 mM Nα-p-tosyl-L-lysine chloromethyl ketone hydrochloride (TLCK),
2 µM pepstatin A and allowed to thaw on ice for 10 min. Cells were vortexed
every 5 min for 30 min, with 20 sec of resting on ice between vortexing. Cell
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lysates were centrifuged for 30 min at 4°C at 16,000 x g to remove cell debris.
Supernatant was removed, aliquotted, snap frozen in liquid nitrogen, and stored
at -80°C.
Streptavidin Blotting
For streptavidin-blotting, lysates were fractionated on 8% SDS-PAGE
gels, transferred to nitrocellulose, and blocked in Wash Buffer (1% dry milk, 1X
TBS, 0.05% Tween-20). Blots were probed for ACC with streptavidin-horseradish
peroxidase conjugate (SA-HRP) (Pierce) diluted 1:200 in Streptavidin Wash
Buffer (0.2% dry milk, 1X TBS, 0.05% Tween-20). Blots were washed 4X in
Streptavidin Wash Buffer, followed by 2 washes in 1X TBS/0.05% Tween-20.
The blots were developed using the Pico SuperSignal Enhanced
Chemiluminescence kit (Pierce), and exposed to HyBlot CL film (Denville). For
some experiments the blot was cut, and the top half probed for ACC with SAHRP as above, while the bottom half was probed for tubulin as follows. Blot was
incubated with a mouse anti-tubulin antibody (clone B-5-1-2 ; Sigma) diluted
1:500,000 in Wash Buffer, washed 4X in Wash Buffer, and probed with HRPconjugated goat anti-mouse IgG antibody (Invitrogen) diluted 1:20,000 in Wash
Buffer. After 4 washes in Wash Buffer and 2 washes in 1X TBS, 0.05% Tween20, blots were developed for ECL. Semi-quantitative analysis of blots was
performed using densitometry (NIH Image J software) of appropriately exposed
films (unsaturated signal within the linear range of the film).
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ACC Enzyme Activity
To assay ACC activity, we modified a biotin carboxylase assay described
previously (Wurtele and Nikolau, 1990). To remove endogenous CoA substrates,
lysates were either dialyzed into BC Buffer (50 mM Tris-Cl pH 8, 5 mM MgCl2, 2
mM DTT) for 4-12h at 4°C or alternatively, were desalted on a G50-80 sephadex
column (Sigma) equilibrated in BC Buffer. Treated lysates were then incubated in
a final volume of 100 µl BC Buffer supplemented with 5 mM ATP, 0.6 mM acetylCoA, 1 mg/ml fatty acid free bovine serum albumin (BSA) (Sigma), and 2 mM
[14C]NaHCO3 (14.9 mCi/mmol) for 30 min at 30°C, mixing every 10 min.
Reactions were stopped by transferring tubes to ice for 5 min. Unreacted
[14C]NaHCO3 was released as [14C]CO2 by the addition of 50 µl 6N HCl. Acidprecipitated [14C]malonyl-CoA product was collected on Whatman #1 filter circles,
air-dried, and quantified by scintillation counting. Linear regressions and Student
t-Test analyses were performed using Microsoft Excel.
Generation of ACC-myc Cell Line
We used an in situ epitope-tagging strategy to generate a procyclic cell
line with the C-terminus of one ACC allele fused to the c-myc epitope. We used
PCR with bipartite primers and the appropriate plasmid template to generate a
936 bp linear tagging construct (ACC-MYC/Phleo/ACC 3’-UTR) with the following
features (in 5’-3’ order): 3’ end of ACC gene fused in-frame with c-myc epitope
ending with stop codon, α/β tubulin intergenic region, phleomycin resistance
gene, 5’ end of ACC 3’ UTR sequence. To make this construct we used a 2-step

57

PCR procedure. First, we used a forward primer comprised of the last 54 bp of
the ACC gene (without stop codon) followed by 6 bp of the c-myc epitope
(5’-GACGAAAGGATGCGGCGTGCGGCCATGCAGGCGCTGGAACGTACAACC
GCGAAGGGCCGCTCTGAGCAA-3’). The reverse primer sequence is
comprised of 21 bp of the phleomycin resistance gene followed by the first 44 bp
of the ACC 3’-UTR
(5’-TAATTCTCATTCCTTGCCTCCAGTGGCGCCGCATCCCACGCCATGTCAG
TCCTGCTCCTCGGCCAC-3). For template DNA, we used the mycPHLEO
plasmid (a generous gift of Dr. Meredith Morris, Clemson University), which
contains the c-myc sequence, α/β tubulin intergenic region, and phleomycin
resistance gene. The resulting amplicon encoding the linear tagging construct
was cloned into the pCR 2.1-TOPO vector and sequenced. For the second PCR
step, we used shorter forward and reverse primers that flank the linear tagging
construct (5’-GACGAAAGGATGCGGCGT-3’, and
5’-TAATTCTCATTCCTTGCCTCC-3’, respectively) to perform a large-scale PCR.
The resulting amplicon (ACC-MYC/Phleo/ACC 3’-UTR) was purified using a
MinElute column (Qiagen), and 15 µg of purified targeting construct was
electroporated into 1 x 108 procyclic form 427 cells and selected in 2.5 µg/ml
phleomycin. Integration of the tagging construct into the genomic locus via
homologous recombination generated an in-frame fusion of the c-myc epitope to
the 3’ end of one allele of ACC. Correct integration was confirmed by diagnostic
PCR and western blotting.
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Sub-Cellular Fractionation
Hypotonic lysates of wild-type and ACC-myc-expressing procyclic form
cells were subjected to differential centrifugation (Bangs et al., 1993; Roggy and
Bangs, 1999). Briefly, lysate and then supernatants were fractionated by three
successive centrifugation steps: a 1,000 x g step yielding P1 (cell fragments,
nuclei, mitochondria) and S1 fractions; a 100,000 x g step yielding P2
(microsomes) and S2 fractions; and a second 100,000 x g step yielding P3
(residual microsomes) and S3 (cytosol) fractions (Fig. 2.6A). Samples of each
sub-cellular fraction (1.5 x 106 cell equivalents) were separated by 10% SDSPAGE and transferred to nitrocellulose. Membranes were processed for
streptavidin blotting as described above. To probe for ACC-myc or sub-cellular
markers, membranes were blocked ≥ 1 h in 5% milk/1X TBS and probed with
primary antibodies diluted in 5% milk/1X TBS/0.5% Tween-20 as follows: antic-myc (clone 9E10), 1:250; anti-glycosome, 1:7,500; anti-cytosolic HSP70,
1:4000; anti-BiP, 1:2000. HRP-conjugated goat anti-mouse or goat anti-rabbit
secondary antibodies (Pierce) were diluted 1:10,000 in 5% milk/1X TBS/0.5%
Tween-20. After washing, blots were developed using ECL and exposed to film
as described above.
Microscopy
Microscopy was performed essentially as described in (Field et al., 2004).
Briefly, wild-type and ACC-myc procyclic cells were harvested by centrifugation
(800 x g, 10 min), washed once with ice-cold Voorheis’s modified PBS (vPBS)
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(Nolan et al., 2000), and fixed on ice in 3% paraformaldehyde (w/v) in vPBS for
1 h. Fixed parasites were adhered to poly-L-lysine treated glass slides and
permeabilized for 10 min in 0.1% Triton X-100 (v/v) in vPBS. Slides were
incubated in microscopy blocking solution (MBS: 0.5% bovine serum albumin
(BSA) (w/v), 5% normal goat serum (v/v), 20% FBS (v/v) in vPBS) for ≥ 1 h.
Primary antibodies were used at the following dilutions in MBS: 9E10 anti-C-myc,
1:100; anti-glycosome, 1:100; anti-cytoplasmic HSP70, 1:1000; anti-BiP 1:1000
(ER marker); and anti-lipoamide dehydrogenase 1:500 (mitochondrial marker).
Secondary antibodies were goat anti-mouse and goat anti-rabbit conjugated to
Alexa Fluor 488 (green) or Alexa Fluor 594 (red) (Invitrogen) diluted 1:750 in
MBS. To stain lipid droplets, cells were incubated with 0.005% Nile Red diluted in
vPBS (Greenspan et al., 1985; Robibaro et al., 2002). The broad emission
spectra of Nile Red prevents the co-staining of lipid droplets and ACC-myc in the
same cells (Wolinski and Kohlwein, 2008). Immediately prior to imaging, the
nucleus and kinetoplast were stained with 4’,6-diamidino-2-phenylindole (DAPI)
(1 mg/mL in vPBS) (Invitrogen) (Field et al., 2004). Images were collected using
a Nikon TE2000 widefield epifluorescence microscope and image acquisition
was performed using the Nikon NIS Elements software package.
RNA Interference
To make the ACC RNAi construct, a fragment bracketing the start codon
of ACC (-110 to +467 nt) was amplified by PCR (Roche Expand High Fidelity)
from wild-type procyclic form 427 genomic DNA using a forward primer
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containing a 5’ Xho I site (5’-CCGctcgagTCCGAGCTCGCAAAGTG-3’) and a
reverse primer containing a 5’ Hind III site
(5’-CCCaagcttGTCGCCCAAAGCAAACATC-3’). This 572 bp amplicon was
cloned first into pCR2.1 TOPO prior to sub-cloning into the tetracycline-inducible
RNAi vector pZJM (Wang et al., 2000). The pZJM.ACC plasmid was confirmed
by sequencing (one T-to-C difference from 927 sequence at nt -55).
Bloodstream and procyclic form RNAi cell lines were generated as
described previously (Wang et al., 2000; Morris et al., 2001), with modifications
suggested by J. Roper and M. Ferguson (pers. comm.). pZJM.ACC plasmid was
linearized by Not I digestion and precipitated in ethanol to a final concentration of
10 mg/ml. Prior to transfection, cells were washed twice in Cytomix (van den Hoff
et al., 1992). For transfection into 29-13 procyclic cells, 100 µg of linearized
pZJM.ACC was electroporated into 1 x 108 washed cells in a final volume of 0.5
ml. A stable non-clonal procyclic ACC RNAi population was established first,
followed by isolation of clonal cell lines by limiting dilution. For transfection into
90-13 bloodstream form cells, 5 replicate transfections were prepared, each
containing 100 µg linearized pZJM.ACC and 3 x 107 washed cells in a final
volume of 0.5 ml. After electroporation, the 5 transfections were pooled and
dispensed into 24 well plates, resulting in clonal cell lines.
For growth curves, ACC RNAi cells were diluted into normal or low-lipid
media, induced for RNAi by the addition of tetracycline (1 µg/ml final) (Wang et
al., 2000) and cell density monitored using either a Z1 dual-threshold Coulter
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Counter (Beckman) or a FACScan flow cytometer (Becton Dickinson). For
comparison purposes, the slopes of the growth curves (linear correlation
coefficients) were derived from linear regressions performed using Microsoft
Excel. Doubling times were calculated from the slopes. Student t-Test analysis
was performed using Microsoft Excel.
Metabolic Labeling and Lipid Analysis
Metabolic labeling was performed essentially as described (Paul et al.,
2004). Briefly, after 7 days of RNAi induction, 1 x 108 cells were washed 3X in
BBSG and resuspended in 1 ml of either HMI-9 (for bloodstream forms) or SDM79 (for procyclics). The 1 ml of cell suspension was then added to tubes
containing 50 µCi of dried down [11,12-3H]laurate (C12:0; 50-60 mCi/mmol) or
[9,10-3H]myristate (C14:0; 50-60 Ci/mmol) and incubated for 2 h in a 37°C
(bloodstream forms) or 28°C (procyclic forms) CO2 incubator. Total lipids were
extracted using a modified Folch method, equal DPMs were loaded per lane
(4,000-10,000), and analyzed by normal phase thin-layer chromatography (TLC)
on Kieselgel 60 plates as described previously (Morita et al., 2000a; Morita et al.,
2000b; Paul et al., 2004). Labeled lipid species were identified based on known
migration patterns in this TLC system (Doering et al., 1993) or co-migration with
the following markers: [3H]myristate for all free fatty acids, [1-14C]dimyristoyl
phosphatidylcholine (American Radiolabeled Chemicals) for the various
phospholipid species, and the bloodstream-specific VSG anchor precursors,
Glycolipids A and C, which were generated using a cell-free
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glycosylphosphatidylinositol anchor biosynthesis reaction (Morita et al., 2000a;
Paul et al., 2004). To analyze the fatty acids by chain length, total lipid extracts
were converted to fatty acid methyl esters (FAMEs), extracted in hexane, equal
DPMs were loaded per lane (4,000-10,000), and analyzed by C18 reverse-phase
TLC (Morita et al., 2000b; Paul et al., 2004). For chain length markers, FAMEs
were prepared in parallel from [11,12-3H]laurate (C12), [9,10-3H]myristate (C14),
[9,10-3H]palmitate (C16), and [9,10-3H]stearate (C18). Semi-quantitative analysis
of TLCs was performed using densitometry (NIH Image J software) of
appropriately exposed autoradiographic films with an unsaturated signal within
the linear range of the film. To determine fatty acid elongation, each FAME spot
was quantified and then calculated as follows: total C12 elongation = 100 x ([C14
+ C16 + C18]/[C12 + C14 + C16 + C18]); total C14 elongation = 100 x ([C16 +
C18]/[C14 + C16 + C18]).
Mouse Infections
Analysis of ACC RNAi in mice was performed essentially as described
(Lecordier et al., 2005). 20 Female NIH Swiss mice (10-12 weeks) were divided
into 2 groups of 10 and pre-treated via their drinking water for 2 days with either
1 mg/ml doxycycline/ 5% sucrose (+ RNAi group) or 5% sucrose alone (no RNAi
group). Doxycycline is a bioavailable tetracycline analog that will induce RNAi in
vivo (Lecordier et al., 2005) and does not itself affect the course of infection
(Rothberg et al., 2006; Abdulla et al., 2008). Mice were then infected by
intraperitoneal injection with 1 x 105 bloodstream form ACC RNAi cells freshly
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thawed from frozen stabilates. Mice were maintained on treated water for the
duration of the experiment, with fresh changes every 2 days. Course of infection
was monitored and time to death was recorded. Parasitemias were monitored
periodically in a randomly selected sub-set of mice by tail stick and examination
of blood smears. Mice were monitored daily for general appearance, behavior,
and weight loss. If a mouse reached a humane endpoint (parasitemia ≥ 108,
>20% weight loss, or obvious distress) the mouse was euthanized and time of
death marked as the following day. Trypanosomes were purified from blood by
DE52 anion exchange chromatography (Lonsdale-Eccles and Grab, 1987) and
equal cell equivalents were assessed for ACC protein by SA-HRP blotting as
described above. Kaplan-Meier analysis was performed using JMP software.
Experiments were carried out in accordance with protocols approved by the
Institutional Animal Care and Use Committee (IACUC) of Clemson University.
ClustalW Alignment of ACCs
Full-length sequence of the TREU 927 T. brucei ACC gene
(Tb927.8.7100) and the Leishmania major ACC gene (LmjF31.2970) were
downloaded from the TriTrypDB genome database (www.TriTrypDB.org (Aslett
et al., 2009)). The Trypanosoma cruzi ACC gene was reconstructed from two
unlinked DNA sequence fragments (TcChr31-S nt 149040-152627 (+2) and
TcChr31-S nt 152824-155282 (+3)) downloaded from TriTrypDB. ACC gene
sequences for Saccharomyces cerevisiae ACC (Accession # AAA20073) and
human ACC1 (Isoform 1, Accession # NP_942131) were downloaded from
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National Center for Biotechnology Information (NCBI). Alignments were
performed using ClustalW (Larkin et al., 2007) followed by some manual
adjustments.
ACC-MYC Immunoprecipitation and ACC Assay
Lysates from 2.5 x 108 cells were created by addition of 600 µl of
hypotonic buffer and vigorous shearing through a 27.5 gauge needle. Lysates
were then centrifuged for 10 min at 1000 x g to remove cellular debris. Following
centrifugation, a 500 µl sample of cleared lysate was aspirated and added to 10
µl of immobilized anti-C-myc agarose beads (5 µg of anti-C-myc antibody in 2.5
µL settled agarose beads) (Thermo Scientific) and incubated end-over-end at
4°C for 1 h. The beads were then centrifuged, washed twice, and resuspended in
150 µl of BC buffer. Two-fold serial dilutions were made in BC buffer and
assayed for ACC enzymatic activity as described in Experimental Procedures.
Total activity was normalized to the “no lysate” control.
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FIGURES
Figure 2.1: T. brucei Acetyl-CoA Carboxylase (TbACC) Gene Structure. A.
Cartoon showing comparative enzyme architectures of T. brucei ACC (TbACC),
Saccharomyces cerevisiae ACC1 (ScACC1), and human ACC1 (HsACC1).
Entire protein sequence (black line) with Biotin carboxylase (BC) domains
(hatched boxes), Biotin Carboxyl Carrier Protein (BCCP) Domains (black boxes),
and Carboxyltransferase (CT) domains (white boxes) are drawn to scale.
Conserved phosphorylation sites are indicated by capital Ps above the line. B.
Alignment of the N-terminal sequences of TbACC, ScACC1, and HsACC1. The
two conserved N-terminal serine phosphorylation sites in HsACC1 are indicated
by shadowboxing. The first part of the conserved Biotin Carboxylase (BC)
domain is in bold text and indicated by black bar underneath the text.
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Figure 2.2: ClustalW alignment of ACC genes from T. brucei, S. cerevisiae
ACC1, and human ACC1. Identical residues are shaded in black, conserved
residues are shaded in gray. ATP-binding motif (ATP) and biotinylation site
(biotin) are boxed. Asterisks mark residues important for binding and/or catalysis
as indicated by the crystal structure and/or mutational analyses.
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Figure 2.3: ClustalW alignment of ACC genes from three trypanosomatids:
T. brucei, T. cruzi, and L. major. Identical residues are shaded in black,
conserved residues are shaded in gray. ATP-binding motif (ATP) and
biotinylation site (biotin) are boxed. Asterisks mark residues important for binding
and/or catalysis as indicated by the crystal structure and/or mutational analyses.
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Figure 2.4: ACC Transcribed in Both Bloodstream and Procyclic Forms. A.
Total RNA (~1 x 107 cell equivalents) was probed for ACC by northern blotting
with a 32P-labelled DNA probe. Loading control is ethidium bromide stained
ribosomal RNAs (EtBr rRNAs). gDNA, genomic DNA. B. Total lysates (20 µg
protein) were probed for ACC by blotting with SA-HRP, which recognizes the
ACC biotin prosthetic group. Loading control is lower half of blot probed for
tubulin. C. ACC activity was measured in lysates (100 µg of protein) of
bloodstream forms (BF; gray bars) and procyclic forms (PF; white bars) by
assaying the conversion of [14C]sodium bicarbonate into the acid-resistant
[14C]malonyl-CoA product, which was dried onto filters and measured by
scintillation counting. Lysate concentration was within linear range for the assay.
Values were normalized to no lysate controls before averaging. Mean of 6
experiments is shown. Error bars indicate the SEM (p >0.5 for difference
between bloodstream and procyclic form activity, Student’s t-Test).
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Figure 2.5: ACC Activity is evident in anti-C-myc immunoprecipitation from
ACC-MYC cell lysate. Lysate from procyclic form ACC-myc cells (light gray
bars) and control 29-13 cells (black bars) were subjected to immunoprecipitation
with anti-c-myc coated latex beads. Washed beads containing bound proteins
were serially-diluted and assayed for ACC activity by measuring the conversion
of [14C]sodium bicarbonate to [14C]malonyl-CoA by scintillation counting of the
acid-resistant product. Total activity of each sample was normalized to the “no
lysate” control.
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Figure 2.6: Sub-Cellular Fractionation Shows ACC to be Cytosolic. A.
Scheme for sub-cellular fractionation by differential centrifugation of lysates
prepared from procyclic form ACC-myc cells. B. Starting lysate (L) and subcellular pellet (P) and supernatant (S) fractions were probed by western blotting
for ACC-myc (c-myc), total ACC (SA-HRP), cytoplasmic HSP70 (cytoplasmic
marker), glycosomes, and BiP (ER marker). The anti-glycosome antibody
recognizes three glycosomal enzymes: pyruvate phosphate dikinase (PPDK)
(~100 kD), aldolase (~41 kD), and glyceraldehyde phosphate dehydrogenase
(GAPDH) (~39 kD). The identity of the ~50 kD band is not known. Example
shown is representative of two independent fractionations.
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Figure 2.7: Immunofluorescence microscopy shows ACC distribution is
distinct from glycosomes. Procyclic form ACC-myc cells were fixed
permeabilized, and ACC-myc (green) localized with mouse anti-c-myc primary
antibody and Alexa-Fluor 488 conjugated goat anti-mouse secondary antibody
(B, F). Glycosomes (red) were localized with rabbit anti-glycosome primary
antibody and Alex-Fluor 594 conjugated goat-anti-rabbit secondary antibody (C,
G). Merged views show the red and green channels (D, H). Cells were co-stained
with DAPI (blue) to indicate nuclear and mitochondrial DNA (A, E). Cells were
imaged at 100X. Scale bars = 10 µm.
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Figure 2.8: Immunofluorescence Microscopy Shows ACC is Localized to
Cytoplasmic Puncta. A–H. Procyclic form ACC-myc cells (A–D) and wild-type
procyclic cells (E–H) were fixed, permeabilized, and ACC-myc localized by
staining with mouse anti-c-myc primary antibody and Alexa-Fluor 488 conjugated
goat anti-mouse secondary antibody (green). I–X. Procyclic form ACC-myc cells
were co-localized for ACC-myc as above (green) along with rabbit antibodies for
various sub-cellular markers: I–L, glycosome (anti-glycosomal); M–P, cytoplasm
(anti-cytoplasmic HSP70); Q–T, ER (anti-BiP); and U–X, mitochondrion (antilipoamide dehydrogenase (LipDH)). Secondary antibody was goat-anti-rabbit
conjugated to Alex-Fluor 594 (red). Y–Z. Wild-type procyclic cells were stained
with Nile red to show lipid droplets. All cells were co-stained with DAPI (blue) to
indicate nuclear and mitochondrial DNA. Cells were imaged at 100X (A, B, E, F,
I–Z) and 60X (C,D,G,H). Scale bars = 10 µm.
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Figure 2.9: RNA interference of ACC in Bloodstream and Procyclic Forms.
A. Total RNA (10-15 µg) was isolated from ACC RNAi cells after 2 days of RNAi
induction (+ RNAi) or from uninduced controls (– RNAi) and probed for ACC by
northern blotting with a 32P-labelled DNA probe corresponding to the ACC RNAi
target sequence. ACC mRNA, the Tet-induced double-stranded RNA (dsRNA),
and contaminating genomic DNA (gDNA) are indicated at the right. Loading
control is ethidium bromide stained ribosomal RNAs (rRNAs). One of 4
independent clones with similar results is shown. B. ACC RNAi cells were
induced for 0–10 days. Total cell lysates (20 µg) from each time point were
probed for ACC by SA-HRP blotting. Blot is over-exposed to show non-specific
cross-reacting bands. A representative of 2 independent experiments is shown.
C. ACC RNAi cells were induced for 4 days and hypotonic lysates from induced
(+ RNAi) and uninduced control cells (no RNAi) were assayed for ACC activity by
measuring the conversion of [14C]sodium bicarbonate to [14C]malonyl-CoA by
scintillation counting of the acid-resistant product. Inset shows SA-HRP blotting
of the same lysates to indicate extent of ACC RNAi. A representative of 2
independent experiments is shown. D. ACC RNAi cells were induced and cell
growth was monitored for 14 days (+ RNAi) in comparison to control uninduced
cultures (no RNAi). Asterisk indicates when RNA was isolated for the northern
blot. A representative of 4 independent experiments is shown.
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Figure 2.10: ACC RNAi reduces ACC activity, but has no effect on growth in
normal media. A. ACC RNAi cells were induced for 4 days and hypotonic
lysates from induced (+ RNAi; closed symbols) and uninduced control cells (no
RNAi; open symbols) were assayed for ACC activity by measuring the
conversion of [14C]sodium bicarbonate to [14C]malonyl-CoA by scintillation
counting of the acid-resistant product. Total activity was normalized to “no lysate”
control. Linear regression of pooled data from all independent experiments is
shown (n=2 for bloodstream (left panel); n=3 for procyclic (right panel)). B. Linear
regression correlation coefficients of ACC activity data in panel A. ACC RNAi
reduced ACC activity by 87 ± 1% and 90 ±1% in bloodstream (gray bars) and
procyclic cells (open bars), respectively. Error bars indicate SEM (p <0.0005 for
difference between No RNAi and +RNAi, Student’s t-Test). C. ACC RNAi cells
were induced (+RNAi) or left uninduced (No RNAi), and cell growth monitored for
up to 14 days. Doubling times for bloodstream (gray bars) and procyclic (open
bars) trypanosomes were determined from 4 independent growth curves. Error
bars indicate SEM (p >0.1 for difference between No RNAi and +RNAi, Student’s
t-Test).

87

88

Figure 2.11: ACC RNAi Reduces Fatty Acid Elongation. A. ACC RNAi cells
were induced for 7 days. Induced (+ RNAi) and uninduced (– RNAi) cells were
then incubated with 50 µCi of [3H]laurate (C12) or [3H]myristate (C14) for 2 h.
Total lipids were extracted in chloroform/methanol (final
chloroform/methanol/water ratio of 10:10:3) and equal DPMS per lane were
loaded and resolved on Kieselgel 60 plates with chloroform/methanol/water
(10:10:3) as the mobile phase. Plates were sprayed with En3Hance, dried, and
exposed to film. Cell type, RNAi conditions, and type of [3H]fatty acid label are
indicated at the top. The origin (O) and lipid markers (M) (myristate (Myr),
phosphatidylcholine (PtdC), and VSG GPI anchor precursors glycolipid C (C) and
A (A)) are indicated at the right. Relative migration of neutral lipids (NL), free fatty
acids (FFA), phospholipids (PL), and VSG GPI synthesis pathway products are
indicated on left. Asterisk indicates putative phosphatidylethanolamine species.
Lane numbers and marker lane (M) are indicated at the bottom. A representative
of two independent experiments is shown. B. The fatty acids in the total lipid
extracts in panel A were converted to FAMEs, extracted in hexane, and equal
DPMs per lane were loaded and resolved by C18 reverse-phase highperformance TLC using chloroform/methanol/water (5:15:3) as the mobile phase.
Plates were sprayed with En3Hance, dried, and exposed to film. RNAi conditions
and type of label are indicated at the top. The origin (O) and lipid markers for
C12, C14, C16, and C18 FAMEs are indicated at the right. Lane numbers and
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marker lane (M) are indicated at the bottom. A representative of two independent
experiments is shown.
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Figure 2.12: Growth of ACC RNAi Cells in Low Lipid Conditions. ACC RNAi
cells were seeded into normal or low-lipid media, induced for ACC RNAi for 10
days, and the cell densities of induced (+RNAi) and uninduced control (No RNAi)
cultures were recorded every other day. A. Bloodstream form ACC RNAi cells in
normal medium (NM), or two types of low-lipid media: medium made with
delipidated FBS (DL) and medium made with only Serum Plus (SP). B. Procyclic
form ACC RNAi in normal medium (NM) or low-lipid medium made with
delipidated FBS (DL). C. Procyclic form ACC RNAi in DL medium or DL medium
supplemented with 35 µM stearate (DL + C18). For all panels, average of three
replicates is shown. Error bars show SEM, but are smaller than the data
symbols.
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Figure 2.13: Pre-adaptation in low lipid media does not alter effect of ACC
RNAi on growth. A. ACC RNAi cells were seeded into normal or low-lipid media,
grown for 10 days (pre-adaptation), then induced for ACC RNAi for an additional
10 days. Cell densities of induced (+RNAi, closed symbols) and uninduced
control (No RNAi; open symbols) cultures were recorded every other day during
the RNAi induction. For each sample, the first medium listed is the pre-adaptation
medium and the second medium listed is the induction medium (e.g. NM/NM
means pre-adapted in NM and induced NM). A. Bloodstream form ACC RNAi
cells in normal medium (NM), or two types of low-lipid media: medium made with
delipidated FBS (DL) and medium made with only Serum Plus (SP). B. Procyclic
form ACC RNAi in normal medium (NM) or low-lipid medium made with
delipidated FBS (DL). Experiment was performed in duplicate.
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Figure 2.14: ACC RNAi Cells Show Reduced Virulence in a Mouse Model of
Infection. Kaplan-Meier survival analysis of mice infected with bloodstream form
ACC RNAi trypanosomes. NIH Swiss mice (10 per group) were pre-dosed in their
drinking water for 48 h with 1 mg/ml doxycycline in 5% sucrose water (+ RNAi) or
5% sucrose water as a control (No RNAi). At 48 h, mice were infected by intraperitoneal injection of 1 x 105 ACC RNAi trypanosomes and monitored for time of
death for 30 days. Mice were maintained on the doxycycline/sucrose or sucrose
water for the duration. Significance was determined by Wilcoxon Test.
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CHAPTER THREE
INHIBITION OF Trypanosoma brucei ACETYL-COA CARBOXYLASE BY
HALOXYFOP
Patrick A. Vigueira and Kimberly S. Paul
Department of Biological Sciences, Clemson University, Clemson, SC
ABSTRACT
Trypanosoma brucei, a eukaryotic pathogen that causes African sleeping
sickness in humans and nagana in cattle, depends on the enzyme acetyl-CoA
carboxylase (ACC) for full virulence in mice. ACC produces malonyl-CoA, the two
carbon donor for fatty acid synthesis. We assessed the effect of haloxyfop, an
aryloxyphenoxypropionate herbicide inhibitor of plastid ACCs in many plants as
well as Toxoplasma gondii, on T. brucei ACC activity and growth in culture.
Haloxyfop inhibited TbACC in cell lysate (EC50 67 µM), despite the presence of
an amino acid motif typically associated with resistance. Haloxyfop also reduced
growth of bloodstream and procyclic form parasites (EC50 of 0.8 mM and 1.2
mM). However, the effect on growth was likely due to off-target effects because
haloxyfop treatment had no effect on fatty acid elongation or incorporation into
complex lipids in vivo.
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INTRODUCTION
Trypanosoma brucei is a protozoan parasite and the etiological agent of
human African trypanosomiasis, also known as African sleeping sickness. The
disease causes significant morbidity and mortality across its range in subSaharan Africa. The World Health Organization estimates that 60 million people
are at risk of contracting sleeping sickness (WHO, 2010). Livestock and working
animals are also susceptible to infection, and the resulting disease, nagana, is
estimated to cause 4.5 billion dollars in trypanosome-related agricultural losses
each year (FAO, Food and Agricultural Organization of the United Nations,
2007).
The public health consequences and enormous economic burden caused
by T. brucei highlight the desperate need for new chemotherapeutic treatments
for these diseases. Currently, available drugs have substantial negative side
effects, and parasite drug resistance is an ever-present concern (Burri, 2010).
Vaccine development is not a viable option. This strategy is confounded by the
parasite’s ability to change its glycoprotein surface coat through a process called
antigenic variation (Horn et al., 2010).
Previously, we reported that T. brucei acetyl-CoA carboxylase (TbACC) is
required to efficiently establish and maintain an infection in a mouse model
(Vigueira et al., 2011). Knockdown of TbACC by RNA interference (RNAi) nearly
doubled the mean time until death, suggesting TbACC is a suitable candidate for
investigation as a drug target. In T. brucei, TbACC exists as a single
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cytoplasmically-disposed isoform. TbACC is a large multidomain enzyme,
consisting of biotin carboxylase, biotin-carboxyl carrier protein (BCCP), and
carboxyl-transferase (CT) domains. ACC catalyzes the first committed step in
fatty acid synthesis (FAS): the ATP-dependent carboxylation of acetyl-CoA to
make malonyl-CoA, the two-carbon donor for FAS (Vigueira et al., 2011). In lieu
of a conventional fatty acid synthase, the parasite utilizes a series of microsomal
elongases (ELO) for the bulk of FAS (Lee et al., 2006). See (Lee et al., 2007) for
review of T. brucei FAS.
ACC has long been recognized as a useful target for chemical intervention
in crop management. The aryloxyphenoxypropionates (FOPs) and the
cyclohexanediones (DIMs) are ACC inhibitors commonly used to control grass
weeds affecting a number of agricultural crops (e.g. leaf vegetables, onion,
strawberry). The FOPs and DIMs target the plastid ACCs of grasses by binding
the CT domain and causing conformational changes that prevent transfer of the
carboxyl group from the BCCP domain to the acetyl-CoA substrate (Delye et al.,
2003; Zhang et al., 2004; Xiang et al., 2009).
Research into weed FOP- and DIM-resistance mechanisms has identified
two amino acid residues in ACC that appear important in determining resistance
status. In the yeast, Saccharomyces cerevisiae, these residues are L1705 and
V1967, and according to the crystal structure, these residues lie in the haloxyfop
binding pocket of the CT domain (Zhang et al., 2004). In rye grass, Lolium
rigidum, a single change from the native I at either of these important residues is
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sufficient to confer resistance to FOPs, specifically haloxyfop (Zagnitko et al.,
2001; Delye et al., 2003). However, a growing body of evidence suggests that
these residues are likely just two of multiple potential residues in the highly
conserved CT domain capable of influencing FOP sensitivity (Zhang et al., 2004;
Zhang et al., 2006a; Zhang et al., 2006b; Liu et al., 2007).
ACC and lipid metabolism have also been identified as potential drug
targets for treating parasitic protozoan infections (Surolia et al., 2001; Roberts et
al., 2003; Paul et al., 2004; Singh et al., 2009). In particular, haloxyfop has been
demonstrated to inhibit the apicoplast-localized ACC of the apicomplexan
parasite Toxoplasma gondii (Zuther et al., 1999). Here, we report the sensitivity
of a second protozoan ACC to haloxyfop. Despite possessing the amino acid
sequence motif typically associated with haloxyfop resistance, TbACC is inhibited
by haloxyfop. We demonstrate that haloxyfop kills insect midgut stage, procyclic
form (PF) and mammalian bloodstream form (BF) parasites in vitro. However, in
vivo lipid metabolism is not detectably influenced upon treatment, suggesting that
the toxicity of haloxyfop to T. brucei cannot be entirely attributed to TbACC
inhibition.
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RESULTS
Effect of FOPs and sethoxydim on TbACC activity
We tested 4 compounds from the FOP family and a single representative
from the DIM family of herbicides for their effect on TbACC enzymatic activity in
PF lysate. TbACC activity is assayed in desalted cell lysate by measuring the
incorporation of the [14C]CO2 from [14C]NaHCO3 into the acid-resistant
[14C]malonyl-CoA product (Vigueira et al., 2011). Haloxyfop was the most potent
inhibitor of the assay with an EC50 of 67 µM, and EC90 of 400 µM (Fig. 3.1E). The
other tested FOPs (clodinafop, fluazifop, quizalifop) and the DIM compound
(sethoxydim) had either no inhibitory activity or had EC50 values >400 µM (Fig.
3.1A-D). As haloxyfop showed promising activity, we used this compound in our
subsequent studies.
TbACC contains residues that confer resistance in other ACCs
Previous work on FOPS has revealed that resistance can be traced to
two key amino acid residues in the haloxyfop binding pocket of the ACC CT
domain, L1705 and V1967 in Saccharomyces cerevisiae (Zhang et al., 2004). In
ACCs that have been experimentally determined to be resistant to inhibition by
haloxyfop, the proteins possess the L/V motif at equivalent positions (Fig. 3.2).
However, in sensitive ACCs, there are typically deviations from this pattern at
either or both positions: L-1705-I or V-1967-I variants. TbACC has an L/V pair
(L1650 and V1912) identical to the yeast L/V pair and would therefore be
predicted to be resistant to haloxyfop.
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Effect of haloxyfop on growth in culture
We have previously demonstrated that RNAi of ACC causes little
reduction in parasite growth rate when cells are cultured in normal media
(Vigueira et al., 2011). Therefore, we sought to determine the maximum
concentration of haloxyfop that could be tolerated by the parasites without having
a major impact on growth rate. For growth of PF cells, haloxyfop concentrations
up to 100 µM had no significant effect on doubling time, though 250 µM
haloxyfop caused a slight, statistically significant increase (Fig. 3.3B). For BF
cells, growth remained unchanged in the presence of up to 250 µM haloxyfop
(Fig. 3.3E). The overall effect on growth rate over ten days was minimal in both
PF and BF parasites (Fig. 3.3A, D), suggesting that potentially lethal, off-target
effects are kept to a minimum at haloxyfop concentrations ≤250 µM. At higher
haloxyfop concentrations (250 µM to 2 mM), we observed a statistically
significant reduction in cell growth over 48 h (Fig. 3.3C, F) with an EC50 of 1.2
mM for PF parasites and an EC50 of 0.8 mM for BF parasites.
We detected a slight effect of the DMSO solvent on growth, with a 9% and
17% reduction in PF and BF parasites, respectively. The effect of 1% v/v DMSO
on BF parasite viability has been quantified previously and is consistent with our
observations (Sharlow et al., 2010).
Effect of haloxyfop on fatty acid elongation
To determine whether haloxyfop treatment targets TbACC in intact cells,
we assessed FA elongation in vivo as T. brucei will readily take up, elongate and
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incorporate exogenous fatty acids into more complex lipids. We used haloxyfop
concentrations that did not exhibit a major growth defect in PF parasites, as our
previous work showed that ACC RNAi inhibited in vivo fatty acid elongation while
showing no growth defect in normal media (Vigueira et al., 2011). After a 4 day
treatment with 10–250 µM haloxyfop, we incubated PF cells with [3H]laurate
(C12:0) and assessed its elongation by the ELO pathway. A chain length
analysis of FAMEs by reverse-phase TLC demonstrated no reduction in the
ability of the parasite to elongate [3H]laurate (C12:0) to longer fatty acids (C14:0,
C16:0, C18:0) upon haloxyfop treatment (Fig. 3.4B). Additionally, normal phase
TLC of bulk lipids revealed no gross differences between haloxyfop-treated and
untreated parasites in the level of incorporation of [3H]laurate into phospholipids,
free fatty acids, or neutral lipids (Fig. 3.4A).
Effect of haloxyfop on ACC protein levels
We next examined the possibility that the parasite compensated for
haloxyfop inhibition by increasing ACC protein expression. ACC protein can be
detected by western blotting with SA-HRP, which recognizes the biotin prosthetic
group of ACC (Nikolau et al., 1985; Haneji et al., 1989; Vigueira et al., 2011).
After 4 days of haloxyfop treatment (10-250 µM), we observed no statistically
significant changes (p >0.01) in ACC protein levels when normalized to β-tubulin
protein levels (Fig. 3.5).
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DISCUSSION
Of the FOP and DIM compounds we tested, haloxyfop had the greatest
inhibitory effect on TbACC activity in lysate (EC50 of 67 µM) (Fig. 3.1). The EC50
for haloxyfop on TbACC was determined with lysate rather than with purified
protein, thus it is difficult to directly compare to other IC50s reported for purified
ACCs. Direct comparison of TbACC to other ACCs is also problematic because
of the lab-to-lab variation in experimental procedure reported in the literature.
With these limitations in mind, the sensitivity of TbACC in cell lysate is most
similar to the moderate sensitivity described for that of the protozoan parasite T.
gondii (IC50 20 µM) (Zuther et al., 1999) and the Norway rat, R. norvegicus (IC50
120 µM), (Kemal et al., 1992). Our data also suggests TbACC is less sensitive to
haloxyfop than the plastid ACCs of ryegrass, corn, and blackgrass (IC50 1-3 µM)
(Secor et al., 1988; De Prado et al., 2000; Delye et al., 2003) and more sensitive
than the ACC CT domain of the yeast, S. cerevisiae (IC50 ~1.1 mM) (Zhang et al.,
2004).
The moderate sensitivity of TbACC to haloxyfop is somewhat surprising
based on the presence of the L/V variant previously determined to confer
resistance to this compound. Amino acid changes at these two positions cause
sensitive plant ACCs to become resistant to FOPS and DIMS (Zagnitko et al.,
2001; Brown et al., 2002; Christoffers et al., 2002; Delye et al., 2003; White et al.,
2005; Zhang et al., 2006a). With the exception of the Norway rat, organisms
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containing native ACCs with L/V variants are comparatively resistant to haloxyfop
(Fig. 3.2).
The finding that TbACC possess the L/V variant and exhibits moderate
sensitivity supports previous work indicating that although these residues appear
important for conferring resistance, they alone are not necessarily predictive of
sensitivity. Other residues in and around the haloxyfop binding pocket are likely
to affect sensitivity and may moderate the effects of any single residue (Zhang et
al., 2004; Zhang et al., 2006a; Liu et al., 2007). Evidently, the sensitivity of ACCs
to haloxyfop lies on a continuum, making it difficult to classify the ACC of any one
organism as either “sensitive” or “resistant”.
Treatment of PF and BF parasites with haloxyfop concentrations up to 250
µM had a minimal effect on parasite growth and doubling time (Fig. 3.3A-B, D-E).
However, this effect was minor compared to the dramatic effect of higher
haloxyfop concentrations on PF and BF parasite growth over 48 h (Fig. 3.3C, F).
BF parasites were slightly more sensitive to haloxyfop treatment than PF
parasites. However, both PF and BF T. brucei were remarkably less sensitive to
haloxyfop than T. gondii (EC50 ~100 µM) (Zuther et al., 1999). We have
previously demonstrated through RNAi experiments that TbACC is largely
expendable in BF parasites in vitro and is only required when PF parasites are
cultured in low-lipid media (Vigueira et al., 2011). Thus, we contend that inhibition
of TbACC by haloxyfop should have little to no consequence on the growth rate
of the parasite in vitro. Consequently, the reduction in growth we observed with
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haloxyfop concentrations >250 µM can be attributed to off-target effects rather
than inhibition of TbACC.
Our previous work demonstrated that reduction of TbACC by RNAi causes
a robust reduction in elongation of fatty acids in PF parasites (Vigueira et al.,
2011). Given that haloxyfop treatment inhibited TbACC activity in lysate, the
inability of haloxyfop to affect FAS in vivo was unexpected (Fig. 3.4). Assessing
the effect of haloxyfop concentrations >250 µM on fatty elongation in vivo was
not feasible, because any observed effects could not be separated from those
resulting from the profound effect of the compound on parasite growth due to
likely off-target effects (Fig. 3.3C, F).
One possible explanation for this disparity between haloxyfop’s effect in
lysate and intact cells could be a compensatory increase in TbACC protein
expression, a possibility that we ruled out (Fig. 3.5). It is also possible that
incomplete inhibition of TbACC allowed available malonyl-CoA pools to remain
high enough that ELO activity appeared unaffected. Alternatively, the apparent
insensitivity of TbACC to haloxyfop in intact cells may be due to the fact that the
compound does not efficiently enter the cell or is partitioned into a cellular
compartment not accessible to TbACC. Haloxyfop’s effect on growth at higher
concentrations (Fig. 3.3C, F) does not negate poor membrane permeability as a
possible explanation because haloxyfop could be acting at the cellular surface to
cause a reduction in growth. Depolarization of the cellular membrane has been
described in plants and is considered a secondary mechanism for the
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graminicide activity of FOPs (Hausler et al., 1991; Shimabukuro et al., 1992;
Ditomaso,1994; Holtum et al., 1994; Wright,1994).
Another possible explanation is that haloxyfop is modified in intact T.
brucei, rendering it unable to bind and inhibit TbACC. Because the haloxyfop
binding pocket lies in a tight space on the face of the ACC protein dimer, any
small modification of the compound could reduce the ability of haloxyfop to bind
and inhibit enzymatic activity (Zhang et al., 2003). Stereochemical inversion of
haloxyfop has been observed previously in rats (Bartels et al., 1989), however
the inhibitory activity of the resulting enantiomer has not been determined.
In summary, we have demonstrated that haloxyfop inhibits TbACC in vitro,
but has no detectable effect on in vivo lipid metabolism, suggesting that the
toxicity of haloxyfop to T. brucei cannot be entirely attributed to TbACC inhibition.
To our knowledge, this is the first report of potential off-target effects of this class
of inhibitors in protozoan parasites. Furthermore, this study highlights the need
for careful characterization of the mechanisms of action of small molecule
inhibitors in lysates as well as in intact cells.
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MATERIALS AND METHODS
Reagents
All chemicals and reagents were purchased from Thermo Fisher Scientific
and Sigma, except: Serum Plus (JRH Biosciences) and streptavidin conjugated
horseradish peroxidase (SA-HRP) (Pierce). Minimum Essential Medium, Iscove’s
Modified Dulbecco’s Medium, and goat anti-mouse-HRP IgG antibody were from
Invitrogen. [14C]NaHCO3 and 3H-labeled fatty acids were from American
Radiolabeled Chemicals. Silica Gel 60 and C18 reverse phase thin layer
chromatography (TLC) plates were from Analtech. The mouse anti-tubulin
antibody (clone B-5-1-2) was from Sigma. Clodinafop (CAS-No: 105512-06-9),
haloxyfop (CAS-No: 74051-80-2), quizalifop (CAS-No: 94051-08-8) and
sethoxydim (CAS-No: 74051-80-2) were from Sigma. Fluazifop (CAS-No: 6933591-7) was from Wako.
Trypanosome strains and media
Wild-type (WT) strain 427 PF and BF T. brucei were provided by Dr. Paul
Englund (Johns Hopkins School of Medicine). BF parasites were grown in HMI-9
medium (Hirumi et al., 1989) containing 10% heat-inactivated FBS/10% Serum
Plus. PF parasites were grown in SDM-79 medium (Brun et al., 1979) containing
10% heat inactivated FBS.
ACC enzyme activity
To assay ACC activity, we modified a biotin carboxylase assay described
previously (Wurtele et al., 1990; Vigueira et al., 2011). Inhibitors were prepared in
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filter-sterilized dimethyl sulfoxide (DMSO) and used as 100X stocks. Lysates
were incubated with inhibitors for 30 min on ice prior to the addition of reaction
components. The final reaction volume of 100 µl contained 5 mM ATP, 1 mM
acetyl-CoA, 1% v/v DMSO and 5 mM [14C]NaHCO3 (14.9 mCi/mmol), and was
incubated for 30 min at 30°C with constant mixing at 500 RPM. A 50 µl sample of
acid-precipitated [14C]malonyl-CoA product was collected on Whatman #1 filters,
air-dried, and quantified by scintillation counting.
Growth experiments
For growth curves, WT cells were diluted into fresh media containing
inhibitors or DMSO solvent control and cell density was monitored every 48 h for
up to 10 days using a FACScan flow cytometer (Becton Dickinson). Inhibitors
were prepared in filter-sterilized DMSO and used as 100X stocks, resulting in
final DMSO concentration of 1% v/v. Following each cell count, cultures were
diluted to maintain logarithmic phase growth, and inhibitors or DMSO was added
to maintain experimental concentrations.
Metabolic labeling and lipid analysis
Metabolic labeling was performed essentially as described (Paul et al.,
2004; Vigueira et al., 2011). Briefly, after 4 days of haloxyfop treatment, ~1 x 108
PF cells were labeled with 25 µCi of [11,12-3H]laurate (C12:0; 60 mCi/mmol) for
2 h in a 28°C CO2 incubator. Total lipids were extracted in
chloroform/methanol/water (10:10:3 v/v/v) and equal CPMs/lane were analyzed
by normal phase TLC using chloroform/methanol/water (10:10:3 v/v/v) as the
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mobile phase. Labeled lipid species were identified based on known migration
patterns in this TLC system (Doering et al., 1993). To analyze the fatty acids by
chain length, total lipid extracts were converted to fatty acid methyl esters
(FAMEs), extracted in hexane, and equal CPMs/lane were analyzed by C18
reverse-phase TLC using chloroform/methanol/water (5:15:3 v/v/v) as the mobile
phase. TLCs were sprayed with En3Hance (Perkin-Elmer) and exposed to x-ray
film at -80°C. For chain length markers, FAMEs were prepared in parallel from 30
µCi of [3H]fatty acids: [11,12-3H]laurate (C12; 60 mCi/mmol), [9,10-3H]myristate
(C14; 60 mCi/mmol), [9,10-3H(N)]palmitate (C16; 60 mCi/mmol), and [9,103

H]stearate (C18; 60 mCi/mmol).

Streptavidin blotting
Streptavidin blotting can detect the biotin prosthetic group on ACC and
was performed essentially as described (Vigueira et al., 2011). Briefly, PF
parasites were treated for 4 days with haloxyfop. 20 µg of whole cell lysate were
fractionated on 8% SDS-PAGE gels and transferred to nitrocellulose. The blot
was cut, and the top half was probed for ACC with SA-HRP (1:400 in 0.2% dry
milk, 1X Tris-buffered saline (TBS), 0.05% Tween-20). The bottom was probed
with a mouse anti-tubulin (clone B-5-1-2), diluted 1:50,000 in Wash Buffer (5%
dry milk, 1X TBS, 0.05% Tween-20) followed by HRP-conjugated goat antimouse IgG secondary antibody diluted 1:10,000 in Wash Buffer. Semiquantitative analysis of blots was performed using densitometry (NIH Image J
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software) of appropriately exposed films (unsaturated signal within the linear
range of the film).
Statistics
One-tailed Student’s t-test analyses between control and treatments were
performed using Microsoft Excel. We judged statistical significance to be p <
0.01. Error bars represent standard deviation from the mean.
Genetic sequence acquisition
ACC protein sequences were acquired from the genetic sequence
database at the National Center for Biotechnical Information. The accession
numbers for each sequence are listed: Trypanosoma brucei (GenBank ID:
XM_842447), Saccharomyces cerevisiae (GenBank ID: NM_001183193), Homo
sapiens ACC1 (GenBank ID: U19822), Homo sapiens ACC2 (GenBank ID:
U89344), Rattus norvegicus (GenBank ID: J03808), Toxoplasma gondii
(GenBank ID: AF157612), Lolium rigidum (GenBank ID: AY995232), Zea mays
(GenBank ID: U19183), and Alopecurus myosuroides (GenBank ID: AJ310767).
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FIGURES
Figure 3.1: Effect of FOP and DIM herbicides on TbACC activity in PF
lysate. ACC activity in PF cell lysates was measured after a 30 min incubation
with 20-400 µM clodinafop (A), fluazifop (B), quizalifop (C), sethoxydim (D), or
haloxyfop (E). Values are expressed as a percentage of the DMSO control.
DMSO concentrations were maintained at 1% v/v for all conditions. The mean of
3 experiments is shown. Error bars indicate the SD. The * indicates p < 0.01 for
the difference between DMSO control and herbicide-treated conditions, Student’s
t-test.
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Figure 3.2: Alignment of multidomain ACC amino acid sequences
surrounding the resistance-conferring residues in the CT domain. The
organism and ACC protein resistance status are indicated in the far left column
(sensitive (S), moderately sensitive (MS), resistant (R)). The resistanceconferring residues, equivalent to S. cerevisiae L1705 and V1967, are
highlighted and the highlighted numbers represent the equivalent amino acid
positions in each sequence. Dashes indicate residues identical to those in T.
brucei. Accession numbers are provided in the far right column. The L. rigidum
sequence is a partial cDNA sequence, thus the highlighted numbers refer to the
amino acid positions in the partial gene product.
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Figure 3.3: Effect of haloxyfop on in vitro growth of T. brucei. A,B,D,E. WT
PF (A,B) and BF (D,E) cells were diluted into media containing 5–250 µM
haloxyfop or DMSO control, and the cell densities of the cultures were recorded
every other day for 8 days. Cumulative culture density is shown in A and D, and
culture doubling times are shown in B and E. C,F. WT PF (C) and BF cells (F)
were diluted into media containing 250 µM–2 mM haloxyfop or DMSO control,
and the cell densities of the culture were determined after 48 h. Values are
expressed as a percentage of DMSO control. For all panels, the mean of three
replicates is shown. Error bars show SD. The * indicates p < 0.01 for the
difference between DMSO and haloxyfop-treated conditions, Student’s t-test.
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Figure 3.4: Fatty acid incorporation and elongation in the presence of
haloxyfop. WT PF cells were grown for 4 days in the presence of haloxyfop or
DMSO. Cells were then incubated with 25 µCi of [3H]laurate (C12) for 2 h. A.
Total lipids were extracted and equal CPMs per lane were resolved by TLC. The
origin (O) and relative migration of neutral lipids (NL), free fatty acids (FFA), and
phospholipids (PL) are indicated on the right. Treatment conditions are indicated
at the top. B. Fatty acid chain length analysis of FAMEs prepared from the total
lipid extracts in (A). Equal CPMs per lane were resolved by C18 reverse-phase
high-performance TLC. The origin (O) and markers for C12, C14, C16 and C18
FAMEs are indicated at the right. Treatment conditions are indicated at the top. A
representative of two independent experiments is shown.

128

Figure 3.5: Effect of haloxyfop treatment on ACC protein levels. WT PF cells
were grown for 4 days in the presence of 25–250 µM haloxyfop or DMSO. A.
Total hypotonic lysates (20 µg protein) were probed for ACC by SA-HRP blotting,
which recognizes the ACC biotin prosthetic group. The lower half of the blot was
probed for tubulin as a loading control. Treatment conditions are indicated at the
top. One representative of three independent blots is shown. B. Densitometric
quantitation of ACC protein levels normalized to the α-tubulin loading control.
Values are expressed as a percentage of the DMSO control. The mean of 3
independent replicates is shown. Error bars indicate the SD. No significant
difference was observed between DMSO and haloxyfop-treated conditions (p >
0.01, Student’s t-test).
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CHAPTER 4
EFFECTS OF THE GREEN TEA CATECHIN EGCG ON Trypanosoma brucei
Patrick A. Vigueira, Ben A. Martin and Kimberly S. Paul
Department of Biological Sciences, Clemson University, Clemson, SC
ABSTRACT
Trypanosoma brucei, a eukaryotic pathogen that causes African sleeping
sickness in humans and nagana in cattle, depends on the enzyme acetyl-CoA
carboxylase (ACC) for full virulence in mice. ACC catalyzes the reaction that
produces malonyl-CoA, the two carbon donor for fatty acid synthesis. We
assessed the effect of the green tea catechin (−)-epigallocatechin-3-gallate
(EGCG) on T. brucei ACC activity and growth in culture. EGCG inhibited TbACC
in cell lysate (EC50 55 µM). However, inhibition of TbACC by EGCG was
dependent upon the presence of phosphatase inhibitors in the cell lysate. EGCG
also reduced growth of bloodstream (BF) and procyclic form parasites at
supraphysiological concentrations (EC50 of 33 µM and 27 µM), but BF growth
was unaffected at physiologically relevant concentrations (<0.1 µM). Additionally,
EGCG treatment did not affect T. brucei virulence in a mouse model.
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RESULTS AND DISCUSSION
The protozoan parasite Trypanosoma brucei is the causative agent of
African sleeping sickness, a fatal human disease that ranges across subSaharan Africa. In addition to causing substantial morbidity and mortality in
humans, T. brucei is responsible for causing nagana, a livestock disease that
results in wasting and death. Nagana imposes a tremendous economic burden
on the region, causing 4.5 billion dollars in economic losses each year (FAO,
Food and Agricultural Organization of the United Nations,2007). Vaccine
development is confounded by the parasite’s ability to switch its surface coat
through antigenic variation (Horn et al., 2010). Thus, chemotherapeutics are
relied upon to battle to the disease, yet currently approved drugs cause
undesirable side effects and can be too expensive for citizens of economically
depressed regions (Castillo et al., 2010). To meet this urgent need, investigations
of existing compounds are an important avenue to identify potential new drugs
that are effective, safe, and economical.
Green tea is among the most widely consumed beverages worldwide and
is often touted for its wealth of medicinal effects (Moon et al., 2007a; Khan et al.,
2008; Thielecke et al., 2009; Ahmed,2010). The best studied active component
of green tea is the catechin (−)-epigallocatechin-3-gallate (EGCG). While EGCG
likely impacts a number of cellular pathways, it has been demonstrated to inhibit
fatty acid synthesis (FAS) (Wang et al., 2001; Brusselmans et al., 2003; Huang et
al., 2009), through its effect on the regulation of acetyl-CoA carboxylase (ACC)
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(Huang et al., 2009). ACC catalyzes the first committed step in FAS, the ATPdependent carboxylation of acetyl-CoA, which provides the two-carbon donor,
malonyl-CoA, for FAS (Lee et al., 2008). ACC is negatively regulated by
phosphorylation by AMP-activated protein kinase (AMPK), a key regulator of
cellular energy metabolism (Barber et al., 2005; Brownsey et al., 2006). EGCG
treatment leads to increased phosphorylation of human ACC, resulting in its
inhibition (Moon et al., 2007b; Huang et al., 2009).
In T. brucei, both the cytoplasmic and mitochondrial FAS pathways are
important for parasite growth in culture and virulence in mouse models (Lee et
al., 2006; Stephens et al., 2007; Vigueira et al., 2011). In addition, we have
demonstrated recently that RNA interference (RNAi)-mediated gene knockdown
of ACC in T. brucei reduced fatty acid elongation activity in intact cells and nearly
doubled the mean time until death in a mouse model of infection (Vigueira et al.,
2011). Taken together, these results suggest that fatty acid synthesis has the
potential to be an effective drug target in T. brucei.
Here, we investigated whether EGCG could be used to target ACC and
fatty acid synthesis in T. brucei. First, we tested EGCG for its ability to inhibit
TbACC enzymatic activity in insect midgut stage, procyclic form (PF) lysate.
TbACC activity is assayed in desalted cell lysate by measuring the incorporation
of the [14C]CO2 from [14C]NaHCO3 into the acid resistant [14C]malonyl-CoA
product, which is then quantified by scintillation counting (Vigueira et al., 2011).
To preserve any changes in phosphorylation caused by EGCG, we added HALT,
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a broad spectrum phosphatase inhibitor, to the cell lysate. In the presence of
HALT, EGCG inhibited TbACC enzymatic activity with an EC50 of 55 µM (Fig.
4.1). However, in the absence of HALT we observed no inhibition of TbACC by
EGCG. These observations are consistent with the previously reported mode of
action of EGCG, inhibition of ACC by increasing its phosphorylation (Moon et al.,
2007b; Huang et al., 2009). We contend that HALT, by inhibiting the parasite’s
native phosphatases, preserved an EGCG-driven increase in ACC
phosphorylation, resulting in decreased TbACC activity. We have made multiple
attempts to quantify EGCG-induced TbACC phosphorylation, but to date we have
been unsuccessful.
We next examined the effect of EGCG on T. brucei growth in culture. In
humans, the maximum reported EGCG plasma concentration achievable through
oral consumption of concentrated green tea catechins ranges from 0.3–1 µM
(Yang et al., 1998; Umegaki et al., 2001; Sugisawa et al., 2002; Unno et al.,
2005). A 6-day treatment of mammalian bloodstream form (BF) parasites at
these physiological EGCG concentrations (0.1–1 µM) caused no change in BF
parasite growth or doubling time (Fig. 4.2A,B). At supraphysiological EGCG
concentrations, we observed a statically significant reduction in cell growth over
48 h (Fig 4.2C,D), with an EC50 of 33 µM and 27 µM for BF and PF parasites,
respectively. These values are consistent with the trypanocidal activity of EGCG
previously reported for T. brucei rhodesiense (IC50 20.3 µM) (Tasdemir et al.,
2006). Based on our previous data showing that TbACC is largely expendable in
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BF parasites in vitro and is only required when PF parasites are cultured in lowlipid media (Vigueira et al., 2011), we contend that inhibition of TbACC by EGCG
should have little consequence on T. brucei growth in culture. Thus, the reduction
in growth observed with EGCG concentrations >5 µM could be attributed to offtarget effects, rather than inhibition of TbACC.
Finally, we examined the effect of EGCG treatment on the course of T.
brucei infection in mice. Although the EC50 values for EGCG for growth in culture
are greater than the maximum reported plasma concentrations in orally-dosed
humans, there were two reasons to justify testing EGCG in a mouse model of
infection. First, T. brucei exhibited condition-specific essentiality in the case of
both TbACC and enoyl-CoA reductase (EnCR); PF ACC and EnCR RNAi cell
lines exhibited slowed growth only when exogenous lipids were limited (Lee et
al., 2006; Vigueira et al., 2011). In addition, TbACC RNAi and TbEnCR
conditional knockout mutants had attenuated virulence in mice (Vigueira et al.,
2011 and Soo Hee Lee, personal communication). Second, previous studies of
EGCG in mice yielded promising results for treatment of trypanosomiasis.
Trypanosoma cruzi mortality in mice and parasite growth in culture was reduced
with EGCG treatment (Paveto et al., 2004; Guida et al., 2007). In addition,
inflammation caused by T. brucei infection was reduced with oral green tea
supplementation in a mouse model (Karori et al., 2008). Taken together, these
observations suggest that the parasite’s sensitivity to EGCG could be higher in
vivo.

139

To test the ability of EGCG to clear a T. brucei infection in mice, we
administered daily IP injections of 4.13 mg/kg EGCG in sterile H2O two days prior
to infection and over the course of the trial. This EGCG concentration had been
previously demonstrated to not cause mouse liver damage, (Guida et al., 2007).
After 2 days of EGCG pre-treatment, Swiss mice were infected with 1x105 BF
wild-type 427 parasites as previously described (Bacchi et al., 2009), and time to
death (or humane end-point) was determined. In this model, EGCG treatment
had no effect on infection duration or mouse mortality. Mean time until death was
~3.5 days for both treatment and control groups (data not shown). Thus, although
EGCG has trypanocidal activity at supraphysiological concentrations, the
compound did not attenuate virulence in an acute infection mouse model. EGCG
concentrations may not have been sufficiently high in the mouse bloodstream to
affect the parasite. Alternatively, it is possible that the course of infection was too
rapid to allow EGCG to exert its effects. If so, then a chronic infection model
might be better suited to examine the efficacy of EGCG as a possible antitrypanosomiasis therapy.
In summary, we found that TbACC is inhibited by EGCG in vitro, and this
inhibition was dependent upon the presence of phosphatase inhibitors in the cell
lysate. This suggests that EGCG could be a useful tool for studying the effects of
phosphorylation on TbACC activity. We also demonstrated that EGCG kills both
PF and BF parasites in culture. However, EGCG treatment did not affect T.
brucei virulence in one mouse model of acute infection.
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FIGURES
Fig. 4.1: Inhibition of TbACC Activity by EGCG. ACC activity in PF cell lysates
was measured in the presence of 5-100 µM EGCG (Sigma) in the absence (Grey
bars) or presence (Black bars) of HALT phosphatase inhibitor cocktail (ThermoPierce). EGCG was prepared in filter-sterilized dimethyl sulfoxide (DMSO) and
used as a 100X stock. HALT was added as a 100X stock per the manufacturer’s
instructions. The final reaction volume of 100 µL contained 5 mM ATP, 1 mM
acetyl-CoA, 1% v/v DMSO and 5 mM [14C]NaHCO3 (14.9 mCi/mmol) and was
incubated for 30 min at 30°C, mixing at 500 RPM. 6N HCl (50 µL) was added to
terminate the reaction, and 50 µL of the acid-precipitated [14C]malonyl-CoA
product was collected on Whatman #1 filters, air-dried, and quantified by
scintillation counting. Values are expressed as a percentage of the DMSO
control. DMSO concentrations were maintained at 1% v/v for all conditions. The
mean of 3 experiments is shown. Error bars indicate the SD. The * indicates p
<0.01 for the difference between DMSO control and EGCG-treated conditions
(Student’s t-test).
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Fig. 4.2: Effect of EGCG on in vitro growth of T. brucei. A and B. WT BF cells
were diluted into HMI-9 media (Hirumi et al., 1989) containing 0.1-1 µM EGCG or
DMSO as the solvent control, and the culture cell densities were monitored for 6
days. Following each cell count, cultures were diluted to maintain logarithmic
phase growth, and EGCG/DMSO was added to maintain experimental
concentrations. Cumulative culture densities are shown in A, and culture
doubling times are shown in B. Please note in A, all points overlap and error bars
are too small to be visible. C and D WT BF (C) and PF cells (D) were diluted into
HMI-9 or SDM-79 media (Brun et al., 1979) containing 5–50µM EGCG or DMSO
control, and the culture cell densities were determined after 48 h. Values are
expressed as a percentage of the DMSO control. For all panels, EGCG was
prepared in filter-sterilized DMSO and used as a 100X stock. The mean of three
replicates is shown. Error bars show SD. The * indicates p < 0.01 for the
difference between DMSO and EGCG-treated conditions (Student’s t-test).
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CHAPTER FIVE
KNOCKDOWN OF Trypanosoma brucei ACYL-COA SYNTHETASE GENES
BY RNA INTERFERENCE
Patrick A. Vigueira and Kimberly S. Paul
Department of Biological Sciences, Clemson University, Clemson, SC
INTRODUCTION
Acyl-CoA synthetases (ACS) are a class of enzymes that catalyze the
thioesterification of free fatty acids (FA) to Coenzyme A (CoA). This process
activates the fatty acids for use in metabolic processes (e.g., α/β-oxidation) and
synthesis of phospholipids, cholesterol esters, ceramides and triglycerides
(Watkins,1997; Soupene et al., 2008; Li et al., 2010). The irreversible, two-step
ping-pong reaction occurs as follows. First, the FA is converted to an acyladenylate, forming AMP and PPi from ATP. Second, the reaction is completed by
esterification of the acyl-adenylate intermediate to CoA through hydrolysis of PPi,
forming the final fatty acyl-CoA product (Watkins,1997; Li et al., 2010).
The human genome codes for five long chain ACS genes (ACSL). The
enzymes’ FA substrates include saturated and unsaturated species ranging from
14-24 carbons. Each ACSL has a unique hierarchy of substrate preferences.
However, many of their substrates overlap, creating redundancy in enzymatic
activity (Soupene et al., 2008). Subcellular localization of the human ACSL1 and
ACSL6 proteins are the best characterized. Both are located on the plasma
membrane, and ACSL1 is tightly associated with fatty acid transport protein 1
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(FATP1) in many cell types. The ACSL1/FATP1 interaction is believed to
enhance FA uptake through vectorial acylation, the coordinated import and
activation of FAs (Soupene et al., 2008).
In addition to the annotated ACS genes, other proteins have been
demonstrated to exhibit ACS activity. Mammalian FATP4 exhibits an intrinsic
ACS activity and has been found to be involved in FA uptake. Despite being
localized to the endoplasmic reticulum rather than the plasma membrane,
expression of FATP4 was reported to correlate with increased fatty acid uptake.
Increased fatty acyl-CoA retention is the proposed mechanism for this
observation. While free FAs can diffuse across membranes and out of the cell,
fatty acyl-CoAs are membrane impermeant and therefore cannot leave the cell
by diffusion (Milger et al., 2006).
The Trypanosoma brucei genome codes for 5 ACS genes based on
homology to previously characterized genes for Leishmania ACS and yeast free
fatty acid receptor 2. Each TbACS contains the characteristic ACS active site that
controls FA binding and enzymatic specificity (Black et al., 1997; Jiang et al.,
2000; Smith et al., 2010). Sequence alignments of TbASC1-4 measured 46-95%
similarity at the nucleotide level and 53-96% similarity at the protein level (Jiang
et al., 2000). The TbASC1-4 genes are organized in a tandem array on
chromosome 9 and the TbACS5 gene resides on chromosome 10 (Jiang et al.,
2000; Aslett et al., 2010). Northern blot analysis revealed that all TbACS1-4
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genes are expressed in both bloodstream (BF) and procyclic (PF) form parasites
(Jiang et al., 2000).
Recombinant versions of the TbACS1-4 genes have been expressed,
purified, and assayed for ACS enzymatic activity (Jiang et al., 2001). TbACS1
had preferences for saturated FAs C11:0 to C14:0. TbACS2 had the highest
specificity, working mainly on C10:0 and C11:0. TbACS3 and TbACS4 had a
very similar substrate preference, not surprisingly because of their 95%
sequence identity; they accommodated a broad range of substrates and
exhibited high affinity for saturated fatty acids C14:0 to C17:0. The substrate
preference of TbACS5 has been less extensively characterized, but early studies
suggest it has the highest affinity for C14:0 (Smith et al., 2010). TbACS1,
TbACS3, and TbACS4 also exhibited high activity on a range of unsaturated FA
substrates; however, TbACS2 activity was restricted to saturated fatty acids
(Jiang et al., 2001).
Here I present experiments that further the characterization of the TbACS
genes. I investigated the collective functional role of the ACS genes in T. brucei
FA uptake and growth. RNA interference (RNAi) of the TbACS genes in PF
parasites had a profound effect on FA uptake and caused a minor reduction in
parasite growth.

150

RESULTS
Generation of panTbACS RNAi cell line
Due to the high level of similarity among the TbACS genes, attempts to
create an RNAi construct for single TbACS gene would likely be unsuccessful.
Therefore, we elected to study the result of simultaneously knocking down all five
of the currently-annotated TbACS genes. To do so, we chose a ~700-bp region
with high homology among the TbACS genes. This region was amplified by PCR,
cloned into the pZJM RNAi vector and stably transfected into PF parasites,
creating a panTbACS RNAi cell line (Wang et al., 2000).
Knockdown of TbACS reduced FA uptake
In order to determine the effect of panTbACS RNAi on T. brucei FA
uptake, cells were incubated with C12:0 or C16:0 FAs conjugated to a non-polar
green fluorescent fluorophore (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-sindacene) (BODIPY), allowing FA uptake to be monitored by measuring cellassociated fluorescence. Upon induction of RNAi, BODIPY-C12:0 (B-C12) and
BODIPY-C16:0 (B-C16) FA uptake was assayed at 48 h intervals (Fig. 5.1).
Induction of RNAi for 2 days caused a 34% reduction in B-C12 uptake (p <0.05)
but had no effect on B-C16 uptake. B-C12 uptake was further reduced after 4
days of RNAi to almost half of the uninduced control (47% reduction, p <0.01).
This was accompanied by a 24% increase in B-C16 uptake (p <0.05). By day 6 of
RNAi induction, B-C12 uptake was reduced further (58% reduction, p <0.01),
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while B-C16 uptake was further increased by 48% relative to the uninduced
control (p <0.01).
Knockdown of TbACS reduced T. brucei growth.
RNAi of panTbACS caused only a small reduction in growth over 6 days of
induction (Fig. 5.2A). This reduction in growth was most evident in a comparison
of cumulative cell densities at the 6-day time point (30% reduction, p <0.01) (Fig.
5.2B). Additionally, doubling time over the 6 days of panTbACS RNAi induction
was increased by ~0.8 h (p <0.05) (Fig. 5.2C).
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DISCUSSION
Knockdown of the TbACS genes by RNAi caused a progressive reduction
in uptake of B-C12 and a corresponding progressive increase in B-C16 uptake
(Fig. 5.1). The former observation is likely due to reduced FA activation by
TbACS, thereby reducing FA retention in the form of activated, membraneimpermeant fatty acyl-CoAs.
The increase in B-C16 uptake was somewhat unexpected and cannot be
directly attributed to TbACS RNAi. We fully expected uptake of B-C12 and B-C16
to respond similarly to TbACS RNAi because both FAs are highly suitable
substrates for TbACS1, TbACS3, and TbACS4 (Jiang et al., 2001). It was clear
that uptake efficiency was very different between the two chain lengths; B-C12
was taken up at a rate ~10 times greater than B-C16 (data not shown). This was
not unexpected, as B-C16 likely does not partition into the plasma membrane as
efficiently due to its longer chain length. Additionally, the rate constant of the
rate-limiting flip-flop reaction is decreased when FA chain lengths are increased
(Kleinfeld et al., 1997).
One possible explanation for the differential consequences of TbACS
RNAi on B-C12 and B-C16 uptake is that the FAs are taken up through two
distinct mechanisms. The parasite, sensing a reduction in FA acquisition due to
TbACS knockdown compensated by up-regulating another FA uptake
mechanism (currently undescribed in T. brucei). This could occur through
increased expression or posttranslational modification of proteins involved in the
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pathway. Assuming B-C12 enters the cell predominately through passive
diffusion and subsequent activation by ACS and B-C16 is taken up primarily
through the presumed upregulated mechanism, this could result in a net
decrease in B-C12 uptake and increase in B-C16 uptake.
These observations represent significant progress towards understanding
the mechanisms of FA uptake in T. brucei. Based on kinetic experiments, it has
long been suspected that the parasite’s FA uptake mechanisms mimic that found
in mammals (Voorheis,1980). However, this is the first direct experimental
evidence that FA uptake is mediated by multiple mechanisms in T. brucei.
The reduction in parasite growth caused by 6 days of panTbACS RNAi
induction was fairly mild (Fig. 5.2A). However, both cumulative cell density and
doubling time showed statistically significant reductions after 6 days of
panTbACS RNAi (Fig. 5.2B,C). This observation is in conflict with the previous
report that TbASC5 is not essential for growth in either PF or BF parasites (Smith
et al., 2010), however it is possible that no single TbACS gene is essential in
isolation because the overlapping activities of the ACS family can compensate
for the loss.
It is also important to note that we detected changes in FA uptake prior to
reduction in parasite growth. This suggests that the observed FA uptake
phenotypes were likely a direct result of, or an immediate response to, TbACS
knockdown and not due to non-specific complications associated with cell death.
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FUTURE DIRECTIONS
In the future, the panTbACS RNAi mutant should be tested for growth in
low-lipid media and FA synthesis rates measured. Evidence from previously
characterized genes involved in T. brucei FA metabolism demonstrates that the
parasite is adaptable to changes in lipid availability. For example, the rate of fatty
acid synthesis was increased when the parasites were cultured in low-lipid media
(Lee et al., 2006). Additionally, RNAi mutants for genes involved in FA synthesis
only exhibited a growth phenotype when cultured in low-lipid media (Lee et al.,
2006; Vigueira et al., 2011). I anticipate that FA synthesis will be upregulated due
to the parasite’s reduced capacity to acquire FA from the environment.
In addition to causing a reduction in B-C12 uptake, presumably TbACS
knockdown also reduced the activation of FAs to CoA esters. This reduction
could be quantified using high-performance liquid chromatography. Because FAs
require activation in order to be incorporated into more complex lipid species, I
anticipate that TbACS knockdown will also lead to an increase in the levels of
free FAs in the parasite. This could be examined by labeling parasites with
[3H]C12:0 and measuring incorporation into complex lipids using densitometric
analysis of total cellular lipid content resolved by thin layer chromatography.
One likely and potentially exciting consequence of panTbACS knockdown
is the reduction in glycophosphatidylinositol (GPI) anchor synthesis. BF T. brucei
depends on the production of copious amounts of a dimyristoyl GPI anchor to
attach its dense surface coat (107 copies per cell) to the plasma membrane. The
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variant surface glycoprotein coat is critical to the parasites ability to evade the
adaptive immune system, and therefore perturbations in the GPI biosynthesis
pathway could compromise the parasites virulence in the mammalian host. This
highlights the importance of extending my studies of TbACS into BF parasites.
Protein modifications by acetylation are also important to the survival of
the parasite. Recently, N-myristoylation has been validated as a drug target. The
myristoyl-CoA:protein N-myristoyltransferase (NMT) is essential for virulence in a
mouse model (Price et al., 2010). The TbACS genes are potentially involved in
generating the myristoyl-CoA used by NMT and could therefore represent drug
targets.
I have provided the first glimpse into the role of ACS in T. brucei’s FA
uptake pathway. However, my studies have barely scratched the surface of what
can be learned about these genes. Many experimental questions pertaining to
TbACS remain unasked. I hope that this work and my thoughts provide a future
Paul Lab student the opportunity to extend our knowledge of these exciting
genes.
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MATERIALS AND METHODS
Trypanosome strains, cell lines, and media
PF T. brucei transgenic cell lines containing genomically integrated
Tetracycline (TET) repressor and T7 polymerase [29-13 (Wirtz et al., 1999)] were
generously provided by Dr. George Cross (Rockefeller University). PF parasites
were grown in SDM-79 medium (Brun et al., 1979) containing 10% heatinactivated FBS and supplemented with 15 mg/ml G418, 50 mg/ml hygromycin
and 2.5 mg/ml phleomycin.

Generation of panTbACS RNAi cell line
To make the panTbACS RNAi construct, an ~700-bp fragment containing
a highly homologous region among the TbACS genes was amplified by PCR
from WT 427 PF genomic DNA using a forward primer containing a 5′ XhoI site
(5′-ctcgagTACTGCGCTTACCTGC-3′) and a reverse primer containing a 5′
HindIII site (5′-aagcttGCCAATGATGCGAAGGGT-3′). This amplicon was first
cloned into pCR2.1 TOPO prior to subcloning into the TET-inducible RNAi vector
pZJM (Wang et al., 2000). The resulting pZJM.panTbACS plasmid was
confirmed by sequencing.
The pZJM.panTbACS plasmid DNA was isolated from 10 mL of overnight
Escherichia coli culture using 2 QIAprep Miniprep columns (Qiagen). 100 µL of
the purified plasmid DNA was linearized in a 200 µL restriction digest containing
20 U of Not1 restriction enzyme (New England Biolabs) for 3 h at 37° C. The
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linearized DNA was then cleaned up using 2 MinElute Reaction Cleanup
columns (Qiagen). Linearized DNA was eluted from the columns in warm sterile
H2O and quantified using a BioPhotometer spectrometer (Eppendorf).
For transfection, 1x108 PF 29-13 parasites were harvested by
centrifugation (10 min, 2500 x G). The parasites were then resuspended in 500
µL of prewarmed Cytomix (van den Hoff et al., 1992) and mixed with 20 µg of
linearized pZJM.panTbACS. A mock transfection that included H2O rather than
DNA was prepared to ensure proper drug selection. The cells were then
electroporated in a 4 mm gap cuvette under the following conditions: exponential
decay mode, 2 pulses with a 10 second interval, capacitance 25 µF, voltage
1.5kV (Djikeng et al., 2004). The cells were then transferred to 40 mL of
prewarmed SDM-79 containing G418 and hygromycin. Phleomycin was added to
the cultures 18 h later to select for successful transfectants. Following drug
selection, clonal populations were established by limiting dilution.
In vitro Growth Experiments
For growth curves, panTbACS RNAi cells were diluted into SDM-79
media, induced for RNAi by the addition of TET (1 mg/ml final) (Wang et al.,
2000). Cell density was monitored using a FACScan flow cytometer
approximately every 48 h (Becton Dickinson). For comparison purposes,
doubling times were calculated for each experimental condition. Following each
cell count, cultures were diluted to maintain logarithmic phase growth.
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Fatty Acid Uptake
FA uptake was monitored at approximately 48 h intervals. To assay FA
uptake, cells were incubated for 20 min at room temperature in a solution of 50%
SDM-79 and 50% Cytomix containing 20 µM B-C12 or B-C16. Following the
incubation, 300 µL of ice-cold Cytomix was added and tubes were chilled on ice
for 2 min. Cells were then washed by centrifugation (2 min, 8000 x g) and
resuspension in Cytomix. Cell-associated fluorescence was measured using a
FACScan flow cytometer (Becton Dickinson). The values were corrected for
background fluorescence by subtracting values collected from an unstained
population of cells. Final values are expressed as a percentage of the uninduced
control.
Statistics
One-tailed Student’s t-test analyses between control and treatments were
performed using Microsoft Excel. We judged statistical significance to be p <
0.05. Error bars represent standard deviation from the mean.
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FIGURES
Figure 5.1: Effect of panTbACS RNAi on T. brucei FA Uptake. PF panTbACS
RNAi parasites were grown in uninduced (no RNAi) or induced (panTbACS
RNAi) conditions and assayed for uptake of B-C12 (A) and B-C16 (B) every other
day for 6 days. All values are expressed as a percentage of the uninduced
control. For both panels, the mean of three replicates is shown. Error bars show
SD. The * indicates p < 0.05 and ** indicates p < 0.01 for the difference
between uninduced and induced RNAi conditions, Student’s t-test.
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Figure 5.2: Effect of panTbACS RNAi on in vitro growth of T. brucei. PF
panTbACS RNAi parasites were grown in uninduced (no RNAi) or induced
(panTbACS RNAi) conditions and cell densities of the cultures were recorded
every other day for 6 days. A. Cumulative culture densities over 6 days. B. Final
cumulative culture densities after 6 days. C. Parasite doubling times. For all
panels, the mean of three replicates is shown. Error bars show SD. Please note
in A, error bars are too small to be visible. The * indicates p < 0.05 and **
indicates p < 0.01 for the difference between uninduced and induced RNAi
conditions, Student’s t-test.
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CHAPTER 6
A FORWARD-GENETIC SCREEN FOR GENES INVOLVED IN Trypanosoma
brucei FATTY ACID UPTAKE
Patrick A. Vigueira, Marianne M. Ligon, Ben A. Martin and Kimberly S. Paul
Department of Biological Sciences, Clemson University, Clemson, SC
INTRODUCTION
In both procyclic (PF) and bloodstream (BF) life stages Trypanosoma
brucei relies on dense glycoprotein surface coats for survival. Procyclin covers
the PF parasite and is believed to protect the parasite from proteolytic
degradation while in the midgut of the tsetse (Richardson et al., 1988; Roditi et
al., 1989). The BF form relies on variant surface glycoprotein (VSG) to evade the
mammalian host’s adaptive immune system (Horn et al., 2010). Both procyclin
(106 copies per cell) and VSG (107 copies per cell) are very densely arranged on
the cells surface. Each glycoprotein is attached to the parasite’s outer membrane
by specialized glycolipids called glycosylphosphatidylinositol (GPI) anchors, each
including two fatty acid (FA) moieties. The high density of essential, GPIanchored surface coat proteins imposes a tremendous requirement for FAs.
The parasite has two options for satisfying its requirement for FAs:
synthesis or uptake. Evidence from previous studies suggests that FA uptake is
preferred over synthesis (Doering et al., 1993; Lee et al., 2006; Vigueira et al.,
2011). Compared to FA synthesis, uptake is highly energetically favorable. For
example, a C16:0 FA that diffuses into a cell and is subsequently activated by
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esterification to a Coenzyme A (CoA) molecule requires the hydrolysis of a single
ATP. In comparison, synthesis of the same C16:0 FA de novo would require 6
ATPs and 12 NADH/NADPH reducing equivalents (Morita et al., 2000; Lee et al.,
2006; Stephens et al., 2007). Despite their importance in the FA metabolism of
the parasite, little is known about the mechanisms or genes involved in T. brucei
FA uptake. I therefore set out to conduct an RNA interference (RNAi)-based
genetic screen to identify genes involved in T. brucei FA uptake.
The creation of an RNAi library by a group of visionary scientists opened
the door to forward-genetic experiments in T. brucei (Morris et al., 2002). The
library was created by cloning sheared fragments of T. brucei genomic DNA
(gDNA) into the pZJM RNAi vector (Wang et al., 2000). The resulting plasmid
library was then stably transfected into procyclic form (PF) parasites. The
coverage of the RNAi library is ~5 fold (Morris et al., 2002; Morris et al., 2005;
Alsford et al., 2011). Thus, upon expansion of the library, each gene in genome
should be represented by multiple parasites. The library has proven to be a
useful tool in identifying novel parasite genes and revealing uncharacterized
biological functions of described genes (Morris et al., 2002; Drew et al., 2003;
Zhao et al., 2008).
To measure FA uptake we utilized a commercially available FA
conjugated to a non-polar green fluorescent fluorophore (4,4-difluoro-5,7dimethyl-4-bora-3a,4a-diaza-s-indacene) (BODIPY). BODIPY-FAs have been
previously validated as useful tools for the study of FA uptake (Li et al., 2005)
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and exhibit properties very similar to unlabeled fatty acids (Zou et al., 2003;
Thumser et al., 2007; Hostetler et al., 2010). Previous studies in our lab have
also validated BODIPY-FAs for use in T. brucei. Cell associated fluorescence
increases with incubation time and FA concentration. My studies of the T. brucei
acyl-CoA synthetases (Chapter 5) demonstrated that RNAi of known FA uptake
genes reduced uptake of BODIPY-C12:0 (B-C12), further validating the basis of
the screen.
In brief, following 4 days of RNAi induction, the library population of cells
were incubated with B-C12 and the dim parasites (those taking up less FA) were
isolated using fluorescence activated cell sorting. Dim parasites were then
subjected to a second round of RNAi induction and FA uptake screening. Clones
with the lowest capacity for uptake were expanded and the RNAi insert was
identified by PCR amplification and subsequent sequencing. Many genes were
identified, but an initial attempt to validate the role of these genes in FA uptake
was unsuccessful. Here I describe the screen in detail and offer suggestions for
future work and screens.
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MATERIALS AND METHODS
Primary FA Uptake Screen
The T. brucei 660-bp RNAi library was thawed from six 1 mL liquid
nitrogen stabilates and allowed to expand for 2 days. In order to achieve the
theoretical 5-fold genome coverage, 200 µL of the expanded RNAi library culture
were seeded into 4 mL of fresh SDM-79 media. Induction of RNAi was initiated
by addition of 1 mg/mL tetracycline (TET) to the media (Wang et al., 2000). The
culture volume was expanded as needed to maintain logarithmic growth, but no
dilutions were made. Following 4 days of RNAi induction, 5 mL of culture
(6.3x106 cells/mL) were utilized for fluorescence activated cell sorting.
The parasites were incubated for 20 min at room temperature in a solution
of 50% SDM-79 and 50% Cytomix (van den Hoff et al., 1992) containing 20 µM
B-C12. Following the incubation, cells were washed twice by centrifugation (2
min, 8000 x g) and resuspension in Cytomix. Cell sorting was conducted in the
Clemson University Cell Analysis Laboratory by the lovely and talented Dr.
Meredith Morris using the Cytopeia Influx fluorescence-activated cell sorter. The
parasites were analyzed using a dot plot (yellow channel, Y-axis and green
channel, X-axis) and gated for normal cellular morphology using the forward and
side scatter detectors. Parasites in the dimmest 1% of the population were
distributed into individual wells of 96-well plates. In total, sixty 96-well plates were
collected.
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Secondary FA Uptake Screen
The 96-well plates were monitored daily for parasite growth. After ~2
weeks of incubation, parasites that had grown to density were diluted into fresh
media in ten 96-well plates. These clonal populations were then subjected to a
second round of screening to further isolate clones that exhibited the strongest
FA uptake phenotype. Prior to RNAi induction, replica plates were generated to
maintain uninduced cell populations for further analysis. RNAi was induced for 4
days prior to FA uptake analysis using a Guava Flow Cytometer. In an attempt to
maximize the dynamic range of the FA uptake assay, cells were incubated with
40 µM B-C12, double the concentration used in the original sort. Following 20
min of incubation, the cells were transferred to a 30 µM filter plate (Millipore)
positioned above a v-bottom 96-well plate. The plates were centrifuged at 4° C
for 10 min at a speed of 3200xG. As the cultures passed through the filter plate,
cellular aggregations were eliminated and individual cells pelleted in the v-bottom
96-well plate. The staining solution was removed by aspiration, and parasites
were resuspended in 200 µL Cytomix. Histogram plots of cell-associated
fluorescence were generated using the 408 nm (yellow channel) detector. The
geometric means of each histogram were used to determine the dimmest 24
clones from each of the ten 96-well plates. The corresponding clonal populations
were transferred from the replica plates into ten 24-well plates for culture
expansion.
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PCR and Sequencing
gDNA was purified from each of the expanded clonal populations using an
STE buffer protocol. Parasites were harvested from 1 mL of dense culture by
centrifugation (3 min, 8,000xG), washed once in Cytomix and resuspended in
200 µL of STE buffer (10 mM Tris-HCl, 1 mM EDTA and 100 mM NaCl). The cell
suspension was then incubated for 10 min in a 95° C heat block and transferred
to ice for 5 min. The lysed cells were then subjected to RNAse treatment (125
µg/mL) for 5 min in a 37° C thermomixer at a speed of 500 RPM. Proteins were
then degraded by proteinase K treatment (250 µg/mL) for 15 min in a 60° C
thermomixer at a speed of 500 RPM. The RNAse and proteinase K were
subsequently inactivated by heating the samples for 5 min in a 95° C heat block.
Following a 5 min incubation on ice, cellular debris was removed by
centrifugation (5 min, 16,000xG).
To determine the gene responsible for causing reduction in FA uptake, the
pZJM insert was amplified from the gDNA using a nested PCR approach
described previously (Morris et al., 2005). The first PCR contained 5 µL of GoTaq
Colorless Mastermix (Promega), 1 µL of each primer PhleoF and AldoR (Morris
et al., 2005) (diluted 1:10 in sterile H2O), 1 µL of freshly-purified gDNA, and 2 µL
of sterile H2O. Thermocycling conditions were as follows: initial denaturation, 94°
C for 2 min; 40 cycles of denaturation, 94° C for 20 sec, annealing, 55° C for 30
sec, extension, 72° C for 2.5 min; final extension 72° C for 5 min. The second
PCR using the internal primers contained 10 µL of GoTaq Colorless Mastermix, 1
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µL of each primer XlinkF and BetaLow (Morris et al., 2005) (diluted 1:10 in sterile
H2O), 1 µL of PCR product from the first reaction and 7 µL of sterile H2O.
Thermocycling conditions were as follows: initial denaturation, 94° C for 2 min; 40
cycles of denaturation, 94° C for 20 sec, annealing, 61° C for 30 sec, extension,
72° C for 2.5 min; final extension 72° C for 5 min. The PCR products were then
subjected to DNA electrophoresis on a 1% w/v agarose gel. The quantity and
purity of the PCR products were assessed by examining the size and number of
bands from each reaction. Reactions that contained a single product were
prepared for direct sequencing.
In order to perform direct sequencing on PCR products, the primers used
in the PCR must be removed. This was accomplished by treatment with
Exonuclease I and Antarctic Phosphatase (exo-AP) (Fisher). A working stock of
exo-AP was prepared by diluting Exonuclease I 1:100 and Antarctic Phosphatase
1:10 in sterile H2O. 1 µL of each PCR product was combined with an equal
volume of the exo-AP enzyme mixture. Samples were then incubated at a
temperature of 37ºC for 30 min and subsequently 80ºC for 15 min.
Following exo-AP treatment, 1 µL of XlinkF primer (diluted 1:10 in sterile
H2O) was added to each sample. PCR products determined to be larger than
1000 bp by DNA electrophoresis were included in a second sequencing reaction
using the BetaLow primer. Sequencing reactions were performed by the
Clemson University Genomics Institute (CUGI). Sequencing results were
analyzed using Sequencher (Gene Codes) and trimmed manually to include only
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high quality sequence. The TriTryp database was utilized to perform BLAST
searches against the T. brucei strain 927 genome (Aslett et al., 2010).
RNAi Cell Line Generation
Four genes were chosen to rebuild RNAi constructs for uptake phenotype
verification: Tb927.7.1310, Tb927.7.6550, Tb11.47.0009, and Tb927.10.14430
identified from clones 1F11, 3B12, 5F10, 6G5, respectively. Primers were
designed to amplify ~ 500 bp region from each of the genes. These genes
fragments were amplified by PCR from wild-type PF 427 genomic DNA using a
forward primer containing a 5′ XhoI site and a reverse primer containing a 5′
HindIII. Each primer also included 4 additional 5’ nucleotides to allow direct
digestion of PCR products. The primer sequences for each gene are as follows:
Tb927.7.1310, pv1F11f.XhoI 5’ –GATCctcgagCGGAGCATCCTAACCAACAG –
3’ and pv1F11r.HindIII 5’ – GATCaagcttTCCCAGGACCAGCCGGAGCG – 3’;
Tb927.7.6550, pv3B12f.XhoI 5’ –GATCctcgagCCATTCTGTGCAATGTGGGG –
3’ and pv3B12r.HindIII 5’ – GATCaagcttTCAAGGTCTCGGTGATGTTG – 3’;
Tb11.47.0009, pv5F10f.XhoI 5’ –GATCctcgagCCTCACGGAGTGTATTAAAC– 3’
and 5F10r.HindIII 5’ – GATCaagcttCAGCCCGAACAACCGGTGAG – 3’;
Tb927.10.14430, pv6G5f.XhoI 5’ – ATCctcgagGGTGGGAATCACCGAGATTG–
3’ and pv6G5r.HindIII 5’ – GATCaagcttCGTGATGTTGTCGCACGACG – 3’.
Following a restriction digest with XhoI and HindIII, the amplicons were ligated
into the TET-inducible RNAi vector pZJM. The resulting plasmids were confirmed
by sequencing.
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Each RNAi construct plasmid was isolated from 10 mL of overnight
Escherichia coli culture using 2 QIAprep Miniprep columns (Qiagen). 100 µL of
the purified plasmid DNA was linearized in a 200 µL restriction digest containing
20 U of Not1 restriction enzyme (New England Biolabs) for 3 h at 37° C. The
linearized DNA was then cleaned up using 2 MinElute Reaction Cleanup
columns (Qiagen). Linearized DNA was eluted from the columns in warm sterile
H2O and quantified using a BioPhotometer spectrometer (Eppendorf). For
transfection 1x108 PF 29-13 parasites were harvested by centrifugation (10 min,
2500 x G). The parasites were then resuspended in 500 µL of prewarmed
Cytomix and mixed with 20 µg of linearized RNAi construct. A mock transfection
that included water rather than DNA was prepared to ensure proper drug
selection. The cells were then electroporated in a 4 mm gap cuvette under the
following conditions: exponential decay mode, 2 pulses with a 10 second interval,
capacitance 25 µF, voltage 1.5kV (Djikeng et al., 2004). Following
electroporation, the cells were transferred to 40 mL of prewarmed SDM-79
containing G418 and hygromycin. Phleomycin was added to the cultures 18 h
later to select for successful transfectants.
Fatty Acid Uptake Experiments
FA uptake was monitored at 2 or 4-day intervals. To assay FA uptake,
cells were incubated for 20 min at room temperature in a solution of 50% SDM79 and 50% Cytomix containing 20 µM B-C12. Cells were then washed by
centrifugation (2 min, 8000 x g) and resuspension in Cytomix. Cell-associated

172

fluorescence was measured using a FACScan flow cytometer (Becton
Dickinson). The values were corrected for background fluorescence by
subtracting values collected from an unstained population of cells. Alternatively,
cells were incubated for 10 min at room temperature in a solution of 50% SDM79 and 50% Cytomix containing 20 µM [3H]-C12. Cells were then washed twice
by centrifugation (2 min, 8000 x g) and resuspension in Cytomix. Cell-associated
radioactivity was measured using an LS-6500 liquid scintillation counter (Becton
Dickinson). Final values are expressed as a percentage of the uninduced or 2913 control.
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RESULTS
In total, BLAST searches identified 99 clones containing pZJM inserts with
high homology to annotated genes from the T. brucei strain 927 genome (Table
6.1). 12 genes were represented multiple times (Table 6.2). One gene,
Tb927.4.1320, was particularly enriched, identified from 32 clones.
I independently assessed 4 of the clonal cell lines (3B12, 3C4, 5B6, 6G5)
for reduced FA uptake following 4 and 6 days of RNAi induction (Fig. 6.2). These
clones were particularly interesting because they contained predicted
transmembrane domains and/or signal peptides, both features of proteins
involved in FA uptake in other organisms. Compared to uninduced controls, only
clone 3B12 exhibited reduced FA uptake on day 4 and 6 of induction. However,
each of the clones exhibited greater than 40% reduction in uptake when
compared to the parental 29-13 control.
Based on the predicted attributes of the genes identified by BLAST
searches, we chose 4 candidates we were interested in further characterizing
(1F11, 3B12, 5F10, 6G5). To generate independent RNAi cell lines for each
candidate gene I cloned a new target sequence that was different from the
original target sequence in the RNAi library into pZJM. Induction of RNAi for 8
days resulted in a 41% reduction in uptake of B-C12 in the pv5F10 cell line (Fig.
6.3B). This reduction in uptake was accompanied by a 56% reduction in growth
(data not shown). RNAi induction in the remaining 3 cones (pv1F11, pv3B12,
pv6G5) did not reduce B-C12 uptake relative to the uninduced controls (Fig. 6.3).
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DISCUSSION AND FUTURE DIRECTIONS
The two most common genes isolated from the screen were Tb927.4.1320
(32 hits) and Tb11.02.2810 (17 hits), both annotated as conserved hypothetical
proteins. According to the InterPro protein analysis and classification database,
Tb927.4.1320 contains a SMAD/FHA domain and Tb11.02.2810 contains an
RNA-binding domain. Thus, both genes are likely involved in gene expression.
While knockdown of these genes may cause reduction in FA uptake, they are of
limited interest to this project because it is unlikely that they are directly involved
in FA uptake. Most likely, these genes cause broad changes in gene expression
that, among other effects, reduces FA uptake.
The screen yielded many potentially interesting genes that should be
independently characterized in the future. For the initial follow-up experiments, I
used a fairly loose set of criteria for prioritizing interest in genes. Genes that
contained predicted transmembrane domains were considered high priority
because many FA uptake genes in other organisms code for integral membrane
proteins. Genes with predicted signal peptides were also of particular interest
because many FA uptake proteins are localized to the cell membrane or
endoplasmic reticulum, both destinations of the secretory pathway.
It is very curious and somewhat disturbing that neither the isolated clones
nor the rebuilt RNAi mutants exhibited consistently reduced FA uptake. Because
we selected the dimmest 1% of the population in the primary sort and then
further narrowed the candidates by 75% in the secondary screen, we should
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have isolated the dimmest 0.25% of the RNAi library at 4 days of RNAi induction.
However, when the clones or genes are tested independently and compared to
uninduced controls, I observed no consistent reductions in FA uptake. It is
difficult to reconcile this observation with the methodology of the screen.
In the 4 tested clones, [3H]-C12 uptake was consistently reduced when
induced RNAi conditions were compared to 29-13 parental controls, but not
uninduced controls (Fig. 6.2). This could potentially be explained by leaky
expression of dsRNA in the uninduced controls, causing a constant induction of
RNAi in the absence of TET in the media. Theoretically, uninduced RNAi mutants
should exhibit phenotypes identical to that of the 29-13 parental parasites, but in
this experiment they do not. This could potentially result in an apparent
dampening or masking of the phenotype upon induction. Leaky expression did
not impact the primary or secondary screen because I did not select clones
based on comparison to uninduced controls. Instead, I chose clones exhibiting
low B-C12 uptake under induced RNAi conditions.
Another possibility is that we selected for clones that were deficient in FA
uptake on the basis of the location of the RNAi vector integration rather that the
RNAi target gene fragment. Typically, linearization of the RNAi construct plasmid
by Not1 restriction digest results in integration into the transcriptionally-inactive
ribosomal spacer region. However, errant integration into alternative genomic loci
could cause the disruption of non-target genes and influence gene-expression
patterns in the surrounding regions. This concept has been demonstrated
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previously (Motyka et al., 2004). This phenomenon has the potential to create
parasites that are deficient in FA uptake and not responsive to RNAi. This is
consistent with my observation that each of the isolated clones exhibited reduced
FA uptake compared to parental 29-13 parasites (Fig. 6.2).
Future screens should avoid this potential problem by using an alternative
methodology for the secondary screen. Rather than utilizing the secondary
screen to select for the dimmest clones, one should compare the uptake of
induced and uninduced RNAi clones. The clones with the greatest reduction in BC12 uptake compared to uninduced controls should be maintained for further
screening. This will help to ensure that the reduced uptake phenotype is a result
of RNAi of the target gene rather than gene disruptions due to errant RNAi
construct integration.
Of the four genes I chose to target with independently constructed RNAi
vectors, only pv5F10 caused a reduction in B-C12 uptake (Fig. 6.3). Clone 5F10
isolated from the screen targeted Tb11.47.0009, annotated as a conserved
hypothetical protein in the TriTryp database. The sequence codes for a protein
with a predicted molecular weight of ~94kD and contains no predicted signal
peptides or transmembrane domains. However, it was of interest to this screen
because it contains a peroxisomal targeting signal and is therefore predicted to
be localized to the glycosome, though it was not included in the report of
glycosome proteomics (Colasante et al., 2006). It is also important to note that
RNAi of Tb11.47.0009 caused a reduction in parasite growth (data not shown).
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While I have demonstrated that RNAi of genes involved in FA uptake can
potentially cause a slowed-growth phenotype (Chapter 5), it is possible that in the
case of Tb11.47.0009, reduced FA uptake was a consequence rather than a
cause of unhealthy cells. Both the reduced FA uptake and growth phenotypes
became apparent following 8 days of pv5F10 RNAi induction, but neither was
detected on day 4. Thus, future studies should include an additional time point at
6 days post-induction to determine which of the phenotypes (reduced uptake or
growth) are exhibited first.
Despite not exhibiting an uptake phenotype, the independently
constructed RNAi cell lines I have generated (pv1F11, pv3B12, pv6G5) should
not be abandoned. The experiments I have presented in this chapter represent a
single experiment using non-clonal cell lines. Clonal cell lines should be
established for each mutant, and the resulting cell lines should be used to repeat
the uptake experiments I have described. In addition, the efficiency of RNAi
knockdown has not been assessed in any of the discussed cell lines.
Recognizing the shortcomings of this RNAi screen, there remains great
potential to find genes involved in FA uptake from the data we have generated.
Within the list there are a number of interesting candidates currently annotated
as hypothetical proteins. These genes should be targeted by conducting FA
uptake and growth assays with independently constructed RNAi mutant cell lines.
Sequencing of RNAi target genes from many of the dim clones was either not
attempted or proved unsuccessful. However, I created liquid nitrogen stabilates
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for all of the clones selected in the secondary screen, so they are available for
further analysis when funding becomes available.
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TABLES AND FIGURES
Table 6.1: FA Uptake Screen Results. Gene annotations, TriTryp gene IDs,
BLAST fragment homology scores, predicted signal peptides (SP) and
transmembrane domains (TMD) from the clones isolated in the FA uptake
screen.
Clone ID
up1A1
up1A8
up1B3
up1B12
up1C6
up1C10
up1D7
up1E10
up1E12
up1F3
up1F11
up1G1
up1G2
up1G3
up1G5
up1G8
up2A6
up2A8
up2C6
up2D3
up2D6
up2E2
up2E3
up2E8
up2F2
up2F4
up2F6
up2G5
up2H2
up2H3
up2H8
up3A3
up3B12
up3C4
up3C7
up3D9
up3E1
up3E9
up3F2
up3F5
up3F6
up3F9
up3G2
up3G10

Gene Annotation
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, conserved
EP1 procyclin
hypothetical protein, unlikely

TriTryp Gene ID
Tb927.4.1320
Tb11.02.2810
Tb11.02.2810
Tb11.02.2810
Tb11.02.2810
Tb927.4.1320
Tb927.4.1320
Tb11.02.2810
Tb11.01.0950
Tb927.4.1320
Tb927.7.1310
Tb927.4.1320
Tb11.02.2810
Tb927.4.1320
Tb11.02.2810
Tb927.4.1320
Tb927.4.1320
Tb927.4.1320
Tb927.4.1320
Tb927.4.1320
Tb11.02.2810
Tb11.01.0950
Tb11.02.2810
Tb927.4.1320
Tb11.01.0950
Tb11.02.2810
Tb11.02.2810
Tb927.4.1320
Tb11.02.2810
Tb927.4.1320
Tb927.4.1320
Tb927.4.1320
Tb927.7.6550
Tb927.7.6550
Tb927.4.1320
Tb927.4.1320
Tb927.4.1320
Tb11.02.2810
Tb927.4.1320
Tb927.1.200
Tb11.02.2810
Tb927.4.1320
Tb927.10.10260
Tb09.160.1350
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BLAST Homology Score
Positives = 378/378 (100% )
Positives = 284/286 (99% )
Positives = 284/286 (99% )
Positives = 284/286 (99% )
Positives = 284/286 (99% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 284/286 (99% )
Positives = 856/1105 (77% )
Positives = 378/378 (100% )
Positives = 471/491 (95% )
Positives = 378/378 (100% )
Positives = 284/286 (99% )
Positives = 378/378 (100% )
Positives = 284/286 (99% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 293/364 (80% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 287/360 (79% )
Positives = 679/710 (95% )
Positives = 284/286 (99% )
Positives = 378/378 (100% )
Positives = 679/710 (95% )
Positives = 284/286 (99% )
Positives = 284/286 (99% )
Positives = 261/336 (77% )
Positives = 282/332 (84% )
Positives = 258/335 (77% )
Positives = 176/197 (89% )
Positives = 378/378 (100% )
Positives = 524/615 (85% )
Positives = 567/614 (92% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 284/286 (99% )
Positives = 306/379 (80% )
Positives = 139/196 (70% )
Positives = 319/332 (96% )
Positives = 378/378 (100% )
Positives = 127/175 (72% )
Positives = 104/143 (72% )

SP, TMD

SP, 1 TMD
SP, 1 TMD

2 TMDs

1 TMD

Clone ID
up4A2
up4B4
up4B6
up4B10
up4C4
up4C10
up4D4
up4D11
up4E6
up4F7
up4G2
up4G8
up4H11
up4H12
up5B6
up5D2
up5E8
up5E10
up5F10
up5G5
up6A10
up6D10
up6F1
up6G5
up7B4
up7C8
up7D2
up7F4
up7G4
up7G9
up7G10
up7H12
up8A12
up8B11
up8B12
up8C12
up8D9
up8F10
up8F12
up8G8
up8H7
up8H10
up8H11
up9B9
up9B12
up9D12
up9E4
up9H2
up10C8
up10F1
up10F2
up10F8
up10G2
up10G9
up10H8

Gene Annotation
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, unlikely
hypothetical protein, unlikely
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
DNA topoisomerase ii
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
succinyl-coA:3-ketoacid-coenzyme A transferase, putative
hypothetical protein, conserved
hypothetical protein, conserved
variant surface glycoprotein, pseudogene
hypothetical protein, unlikely
variant surface glycoprotein, pseudogene
expression site-associated gene, pseudogene
hypothetical protein, conserved
hypothetical protein, conserved
variant surface glycoprotein-related, putative
hypothetical protein, conserved
hypothetical protein, conserved
leucine-rich repeat protein, putative
hypothetical protein
hypothetical protein,chrXI additional, unordered contigs
hypothetical protein, conserved
SL RNA
RNA-editing complex protein,KREPB6
UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase
hypothetical protein, unlikely
hypothetical protein, conserved
ARP2/3 complex subunit, putative
hypothetical protein, conserved
hypothetical protein, conserved
Variant surface glycoprotein, pseudogene
helicase, putative
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, unlikely
retrotransposon hot spot protein, pseudogene
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TriTryp Gene ID
Tb927.1.200
Tb927.4.1320
Tb927.4.1320
Tb09.160.1350
Tb927.1.460
Tb927.1.460
Tb927.4.1320
Tb927.1.200
Tb927.4.1320
Tb927.4.1320
Tb927.4.1320
Tb11.02.2810
Tb927.4.1320
Tb927.4.1320
Tb11.18.0010
Tb09.160.4090
Tb927.5.700
Tb11.01.5780
Tb11.47.0009
Tb11.01.5780
Tb11.01.6610
Tb11.02.2810
Tb11.01.0950
Tb927.10.14430
Tb927.4.1320
Tb11.02.0290
Tb927.5.2610
Tb11.01.6610
Tb11.v4.0020
Tb09.160.0590
Tb11.57.0045
Tb927.2.910
Tb927.6.620
Tb11.02.2810
Tb09.244.2240
Tb927.3.1550
Tb927.4.1320
Tb927.3.1490
Tb927.3.1230
Tb11.1770
Tb927.4.1320
Tb09_SLRNA_0004
Tb927.3.3990
Tb10.v4.0244
Tb09.160.0590
Tb927.5.2610
Tb927.2.2900
Tb927.5.3550
Tb09.244.0440
Tb09.160.0220
Tb927.5.3940
Tb09.160.0590
Tb11.18.0010
Tb09.160.0590
Tb927.1.240

BLAST Homology Score
Positives = 118/149 (79% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 93/143 (65% )
Positives = 82/116 (70% )
Positives = 84/118 (71% )
Positives = 378/378 (100% )
Positives = 61/93 (65% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 378/378 (100% )
Positives = 284/286 (99% )
Positives = 378/378 (100% )
Positives = 349/378 (92% )
Positives = 95/107 (88% )
Positives = 501/522 (95% )
Positives = 756/885 (85% )
Positives = 227/282 (80% )
Positives = 840/895 (93% )
Positives = 251/251 (100% )
Positives = 294/327 (89% ),
Positives = 330/334 (98% )
Positives = 998/1065 (93% )
Positives = 813/1014 (80% )
Positives = 381/387 (98% )
Positives = 35/37 (94% )
Positives = 225/225 (100% )
Positives = 300/333 (90% )
Positives = 162/238 (68% )
Positives = 69/69 (100% )
Positives = 198/267 (74% )
Positives = 571/1006 (56% )
Positives = 102/102 (100% )
Positives = 284/286 (99% )
Positives = 219/294 (74% )
Positives = 114/114 (100% )
Positives = 344/387 (88% )
Positives = 136/137 (99% )
Positives = 379/393 (96% )
Positives = 247/293 (84% )
Positives = 121/148 (81% )
Positives = 55/58 (94% )
Positives = 74/74 (100% )
Positives = 258/264 (97% )
Positives = 51/53 (96% )
Positives = 208/221 (94% )
ositives = 530/546 (97% )
Positives = 688/740 (92% )
Positives = 62/81 (76% )
Positives = 812/895 (90% )
Positives = 77/96 (80% )
Positives = 64/65 (98% )
Positives = 108/110 (98% )
Positives = 64/65 (98% )
Positives = 764/846 (90% )

SP, TMD
2 TMDs

1 TMD
2 TMDs
2 TMDs
2 TMDs

SP, 7 TMDs

2 TMDs

SP, 3 TMDs

SP, 3 TMDs

SP

SP, 3 TMDs
SP, 7 TMDs
SP, 3 TMDs

Table 6.2: Genes Isolated Multiple Times. Gene annotations, TriTryp gene IDs,
and number of isolated clones.
Gene Annotation
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, unlikely
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, conserved
hypothetical protein, unlikely
hypothetical protein, conserved
hypothetical protein, conserved

TriTryp Gene ID
Tb927.4.1320
Tb11.02.2810
Tb09.160.0590
Tb11.01.0950
Tb927.1.200
Tb09.160.1350
Tb11.01.5780
Tb11.01.6610
Tb11.18.0010
Tb927.1.460
Tb927.5.2610
Tb927.7.6550
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# of hits
32
17
4
4
3
2
2
2
2
2
2
2

Figure 6.1: FA Uptake RNAi Screen Flowchart.
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Figure 6.2: FA Uptake in Clones Isolated From the Screen. 29-13 parental
cell lines and clonal parasite populations isolated from the screen were grown in
uninduced or induced conditions for 4 (A) or 6 (B) days and assayed for uptake
of [3H]-C12. All values are expressed as a percentage of uninduced (black bars)
or 29-13 (grey bars) controls.

184

Figure 6.3: FA Uptake in Independently Constructed RNAi Parasites.
Independently constructed RNAi parasites were grown in uninduced or induced
conditions for 4 (black bars) or 8 (grey bars) days and assayed for uptake of BC12. All values are expressed as a percentage of uninduced controls.

185

REFERENCES
Alsford S., Turner D.J., Obado S.O., Scnchez-Flores A., Glover L., Berriman M.,
Hertz-Fowler C., and Horn D. (2011) High-throughput phenotyping using
parallel sequencing of RNA interference targets in the African
trypanosome. Genome Res 21: 915-924.
Aslett M., Aurrecoechea C., Berriman M., Brestelli J., Brunk B.P., Carrington M.,
et al. (2010) TriTrypDB: A functional genomic resource for the
Trypanosomatidae. Nucleic Acids Res 38: D457-62.
Colasante C., Ellis M., Ruppert T., and Voncken F. (2006) Comparative
proteomics of glycosomes from bloodstream form and procyclic culture
form Trypanosoma brucei brucei. Proteomics 6: 3275-3293.
Djikeng A., Shen S., Tschudi C., and Ullu E. (2004) Analysis of gene function in
Trypanosma brucei using RNA interference. In Parasite Genomics
Protocols. Melville, S.E. (ed). Totowa, New Jersey: Humana Press, pp.
287.
Doering T.L., Pessin M.S., Hoff E.F., Hart G.W., Raben D.M., and Englund P.T.
(1993) Trypanosome metabolism of myristate, the fatty acid required for
the variant surface glycoprotein membrane anchor. J.Biol.Chem. 268:
9215-9222.
Drew M.E., Morris J.C., Wang Z., Wells L., Sanchez M., Landfear S.M., and
Englund P.T. (2003) The adenosine analog tubercidin inhibits glycolysis in
Trypanosoma brucei as revealed by an RNA interference library. J Biol
Chem 278: 46596-600.
Horn D., and McCulloch R. (2010) Molecular mechanisms underlying the control
of antigenic variation in African trypanosomes. Curr Opin Microbiol 13:
700-705.
Hostetler H.A., Balanarasimha M., Huang H., Kelzer M.S., Kaliappan A., Kier
A.B., and Schroeder F. (2010) Glucose regulates fatty acid binding protein
interaction with lipids and peroxisome proliferator-activated receptor alpha.
J Lipid Res 51: 3103-3116.
Lee S.H., Stephens J.L., Paul K.S., and Englund P.T. (2006) Fatty acid synthesis
by elongases in trypanosomes. Cell 126: 691-699.
Li H., Black P.N., and DiRusso C.C. (2005) A live-cell high-throughput screening
assay for identification of fatty acid uptake inhibitors. Anal Biochem 336:
11-19.

186

Morita Y.S., Paul K.S., and Englund P.T. (2000) Specialized fatty acid synthesis
in African trypanosomes: Myristate for GPI anchors. Science 288: 140-3.
Morris J.C., Wang Z., Motyka S.A., Drew M.E., and Englund P.T. (2005) An
RNAi-based genomic library for forward genetics in the African
trypanosome. In Gene Silencing by RNA Interference: Technology and
Application. Sohali, M. (ed). Boca Raton, FL: CRC Press, pp. 241.
Morris J.C., Wang Z., Drew M.E., and Englund P.T. (2002) Glycolysis modulates
trypanosome glycoprotein expression as revealed by an RNAi library.
Embo J 21: 4429-38.
Motyka S.A., Zhao Z., Gull K., and Englund P.T. (2004) Integration of pZJM
library plasmids into unexpected locations in the Trypanosoma brucei
genome. Mol Biochem Parasitol 134: 163-7.
Richardson J.P., Beecroft R.P., Tolson D.L., Liu M.K., and Pearson T.W. (1988)
Procyclin: An unusual immunodominant glycoprotein surface antigen from
the procyclic stage of African trypanosomes. Mol.Biochem.Parasitol. 31:
203-216.
Roditi I., Schwarz H., Pearson T.W., Beecroft R.P., Liu M.K., Richardson J.P., et
al. (1989) Procyclin gene expression and loss of the variant surface
glycoprotein during differentiation of Trypanosoma brucei. J.Cell.Biol. 108:
737-746.
Stephens J.L., Lee S.H., Paul K.S., and Englund P.T. (2007) Mitochondrial fatty
acid synthesis in Trypanosoma brucei. J Biol Chem 282: 4427-36.
Thumser A.E., and Storch J. (2007) Characterization of a BODIPY-labeled
fluorescent fatty acid analogue. binding to fatty acid-binding proteins,
intracellular localization, and metabolism. Mol Cell Biochem 299: 67-73.
van den Hoff M.J., Moorman A.F., and Lamers W.H. (1992) Electroporation in
'intracellular' buffer increases cell survival. Nucleic Acids Res 20: 2902.
Vigueira P.A., and Paul K.S. (2011) Requirement for acetyl-CoA carboxylase in
Trypanosoma brucei is dependent upon the growth environment. Mol
Microbiol 80: 117-132.
Wang Z., Morris J.C., Drew M.E., and Englund P.T. (2000) Inhibition of
Trypanosoma brucei gene expression by RNA interference using an
integratable vector with opposing T7 promoters. J Biol Chem 275: 401749.

187

Zhao Z., Lindsay M.E., Roy Chowdhury A., Robinson D.R., and Englund P.T.
(2008) p166, a link between the trypanosome mitochondrial DNA and
flagellum, mediates genome segregation. EMBO J 27: 143-154.
Zou Z., Tong F., Faergeman N.J., Borsting C., Black P.N., and DiRusso C.C.
(2003) Vectorial acylation in saccharomyces cerevisiae. Fat1p and fatty
acyl-CoA synthetase are interacting components of a fatty acid import
complex. J Biol Chem 278: 16414-16422.

188

CHAPTER 7
CONCLUSIONS
Lipid metabolism in Trypanosoma brucei is an often-overlooked aspect of
the parasite’s biology. The existing body of research is outstanding and provides
a solid theoretical and methodological foundation on which to design future
studies. However, many genes that are likely involved in lipid metabolism remain
unstudied. This is surprising because of the unique and essential nature of these
metabolic pathways. The parasite’s utilization of microsomal elongases as a de
novo fatty acid synthesis pathway is novel and many of the characterized genes
represent potential drug targets.
The research I have presented in this dissertation has added to our
growing knowledge of Trypanosoma brucei’s lipid metabolism. In the process we
have established acetyl-CoA carboxylase (ACC) as a potential drug target.
Knockdown of ACC caused a doubling in the mean time until death in a mouse
model. However, we did not cure the mice of the infection and they eventually
succumbed. In the future, conditional knockouts for ACC should be generated
and tested for virulence in mice.
Beyond adding to a long list of potential drug targets, our study has also
demonstrated the importance of experimental flexibility when investigating
potentially essential genes. Many investigations of individual genes and even
genetic screens targeting essential genes examine parasite growth in normal
culture media. This methodology leaves many essential genes unidentified. I
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realize that investigating each gene’s contribution to virulence in a mouse model
is not feasible and would be a foolish endeavor. Instead, media components can
be altered to more closely mimic physiological conditions in the mammalian
bloodstream and cerebrospinal fluid. I fully anticipate that subtle changes in
media composition would influence the outcome of many experiments.
As a follow-up to the ACC characterization, the consequences of ACC
knockdown by RNA interference should be defined. This is the focus of an
ongoing project in the lab. The metabolic or functional consequences of ACC
RNAi, rather than loss of ACC, were the direct causes of reduced parasite
virulence. Defining these consequences would allow us to expand our
investigation to other genes potentially involved in that particular cellular process.
For example, if we determine that ACC RNAi causes of reduced endocytosis
rates, other genes involved in endocytosis could potentially result in a similar
reduction in parasite virulence.
This concept is not unique, as many researchers attempt to identify the
cause of cell death brought on by RNAi. However, because RNAi of most
essential genes results in cell death in vitro, this endeavor is often fruitless. When
a cell is dying, it becomes difficult to define whether a phenotype is a cause,
direct consequence, or indirect consequence of cell death. In the case of ACC
we can avoid this potential problem because the gene is essential for growth only
under certain conditions. Thus, the elaborated phenotypes brought on by RNAi of
ACC can be studied in isolation of cell death.
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I hope that the information and thoughts I have shared in this dissertation
will be useful to future researchers. With a little hard work and a lot of luck this
work could lead to a treatment for African trypanosomiasis, resulting in the
economic revitalization of Sub-Saharan Africa, a region of the world too long
oppressed by the shadow of the tsetse.
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